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RESMEN 
A pesar de los esfuerzos realizados durante más de un siglo en la investigación 
para suprimir la malaria, esta enfermedad sigue siendo una amenaza importante y 
creciente para la salud pública y el desarrollo económico de países en las regiones 
tropicales y subtropicales del mundo. La malaria humana está causada por la infección 
de parásitos intracelulares del género Plasmodium que se transmiten por mosquitos 
Anopheles. De las cinco especies de Plasmodium que infectan a seres humanos, las 
infecciones causadas  por Plasmodium falciparum (P. falciparum) son las que muestran 
mayor tasa de mortalidad. Debido al incremento en la resistencia de P. falciparum a 
fármacos antimaláricos, estudios recientes sugieren que el número de los casos de la 
malaria puede doblarse en 20 años (WHO, 2007). El descubrimiento de una vacuna 
contra malaria representa por lo tanto una necesidad médica urgente para la extensa 
población que vive en áreas donde la malaria es endémica. La vacuna ideal contra esta 
enfermedad debería tener un coste de producción bajo, ser extremadamente segura y 
capaz de inducir inmunidad a largo plazo. Igualmente sería deseable que la vacuna 
fuera activa contra todas las cepas del parásito, dando lugar a la interrupción casi 
completa del ciclo vital de la malaria por la respuesta inmune inducida por la vacuna. 
Aunque se han obtenido resultados prometedores, en particular con vacunas de 
subunidades, el progreso de hacer una vacuna de la malaria se ha visto obstaculizado 
debido en parte a la extensa diversidad genética de  los antígenos candidatos para la 
vacuna. En la vacunación por subunidades, los antígenos, parciales o completos, se 
identifican a partir del complemento proteómico con el objetivo de inducir inmunidad 
protectora frente al patógeno completo tras la vacunación. Durante el ciclo vital del P. 
falciparum, varios antígenos polimórficos del parásito se exponen al sistema inmune 
humano. Entre éstos, el antígeno-1 de la membrana apical (AMA1), la proteína de 
superficie del merozoito (MSP-1) y la proteína del circumesporozoito (CSP) son los más 
estudiados para el desarrollo de una posible vacuna. Los datos epidemiológicos 
sugieren que los anticuerpos adquiridos naturalmente contra las proteínas del 
merozoito (AMA1 y MSP1) contribuyen a la adquisición de la inmunidad protectora en 
áreas endémicas de malaria. Sin embargo, la alta variedad de polimorfismos 
antigenicos en estas proteínas continúan frustrando su uso en vacunas. 
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La inmunidad naturalmente adquirida, tanto en humanos como en modelos 
animales puede ser una herramienta valiosa para el desarrollo de una vacuna capaz de 
prevenir totalmente la infección, o bien la enfermedad severa y muerte. Sin embargo, 
los antígenos y los epítopos específicos que participan a la protección son en gran 
parte desconocidos, y su correlación con la protección observada después de la 
inmunización experimental o de la exposición natural al parásito no se ha podido 
establecer aún. El reto para el posible desarrollo de una vacuna basada en la 
información derivada de la inmunidad adquirida es entender cuáles de las muchas 
respuestas antígeno-específicas frente a Plasmodium son las predominantes y  
responsables en la protección. 
Para ello, es necesario desarrollar nuevas estrategias metodológicas que 
permitan identificar antígenos altamente inmunogénicos. En el primer capítulo de este 
trabajo, hemos desarrollado una metodología que permite la identificación de nuevos 
antígenos expuestos durante la fase eritrocítica del parásito. Brevemente, en este 
estudio, se ha optimizado un protocolo de aislamiento y purificación de 
inmunoglobulinas, mayoritariamente del tipo IgG, que se desarrollan en ratones ICR 
durante una infección por la cepa letal Plasmodium yoelii yoelii 17XL. Un porcentaje 
elevado de ratones ICR muestran una respuesta inmune humoral eficaz frente a la 
infección por Plasmodium yoelii yoelii 17XL, lo que les permite superar la infección 
quedando inmunizados frente a reinfecciones. Las inmunoglobulinas IgG presentes en 
los sueros inmunes de ratón se aislaron y purificaron del resto de proteínas séricas 
utilizando columnas de afinidad Proteina A/G. Las inmunoglobulinas se inmovilizaron 
covalentemente en columnas de agarosa que, a su vez, sirvieron para ensayar un 
protocolo de aislamiento de antígenos de P. yoelii capaces de unirse a estos 
anticuerpos. Los resultados obtenidos indican que las inmunoglobulinas purificadas, de 
acuerdo al protocolo experimental desarrollado, mantienen su estructura funcional y 
son útiles para la selección de antígenos reactivos, por lo que pueden ser utilizadas en 
todos aquellos estudios dirigidos hacia la caracterización de la respuesta inmune 
humoral frente a la malaria y el desarrollo de nuevas vacunas. Usando espectrometria 
de masas para analizar las proteínas del parásito aisladas por inmunoafinidad, se 
identificaron 4 proteínas de Plasmodiu: i) protein-disulfuro isomerasa, ii) un miembro 
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de la familia de proteínas 70 heat-shock, iii) plasmepsina y iv) la subinidad de 39 kDa-
del factor 3 de iniciación eucariótico. Aunque no se pudieron identificar por 
espectrometría otros antígenos previamente descritos como dianas en la vacunación 
frente la malaria, en los geles 1D del eluído tras la purificación de los antígenos sí se 
observaron bandas que podrían corresponder a la subunidad MSP1-19 y sus 
precursores. 
El segundo  capítulo de este estudio se planteó con el objetivo de examinar si 
los antígenos purificados y aislados mediante inmunoafinidad pueden inducir una 
inmunidad protectora frente a la fase sanguínea de la infección por  P. yoelii 17XL. Para 
ello se realizó un primer ensayo de vacunación comparando las formulaciones de 
adyuvante CpG ODN1826  y Freund´s completo (CFA) e incompleto (IFA) sobre ratones 
BALB/c, sensibles a la infección por P. yoelii 17XL. Utilizando una carga elevada de 
parásito en la infección en combinación con cantidades limitantes de antígenos, el 
sistema de Freund´s mostró cierto grado de protección. En un segundo test, utilizando 
dosis mayores de mezcla de antígenos y tres dosis vacunales, se observó una amplia 
respuesta inmune frente a extractos totales de P. yoelii, analizada mediante Western-
blots a diferentes tiempos post-tratamiento en todos los ratones vacunados. A pesar 
de la evidente respuesta inmune a los antígenos purificados por inmunoafinidad, los 
ratones vacunados e infectados con dosis letales de P. yoelii 17XL mostraron diferentes 
niveles de protección. Aunque ninguno de los individuos sobrevivió a la infección, el 
20% de los ratones sobrevivieron más de 14 días, y el 50% sobrevivió un día más en 
promedio que los controles, lo que sugiere que se produce cierto grado de protección 
mediada por la mezcla de antígenos utilizada en el ensayo. En este capítulo se discuten 
los posibles efectos que pueden tener los distintos antígenos en la protección contra la 
malaria letal en el modelo de ratón.   
Como se ha mencionado anteriormente, la información acumulada sobre 
estudios de la vacunas en la malaria sugieren que muchas proteínas desconocidas 
hasta ahora están implicadas en la protección contra la infección. El tercer capítulo de 
este estudio se ha dirigido a la identificación de antígenos tras la infección con 
Plasmodium en poblaciones de ratones ICR, parcialmente resistentes a malaria, 
mediante técnicas inmunoquímicas e inmunoproteómicas. Trabajos previos de este 
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laboratorio han demostrado que, durante la infección con P. falciparum, los patrones 
de oxidación de proteínas, tanto del parásito como del huésped, sufren cambios 
significativos. Por esta razón, la identificación de las proteínas de parásito carboniladas 
en ratones infectados puede ser una estrategia valiosa para el descubrimiento 
adicional de los antígenos aún no identificados y que se puedan utilizar como dianas 
en nuevas vacunas. 
Mediante la comparación de los patrones obtenidos tras transferencia a parejas 
de membranas de geles 2-D de proteína de P. yoelii, la primera revelada con suero 
obtenido de los ratones ICR infectados y la segunda revelada con anti-2,4-
dinitrofenilhidracina (DPNH) tras derivatización con DPNH de las proteínas 
transferidas, se han podido identificar varias proteínas carboniladas del parásito con 
actividad inmunogénica en los ratones ICR infectados. Mediante espectrometría de 
masas de los péptidos generados por digestión con tripsina, las proteínas se 
identificaron, resultando pertenecer a tres clases: el primero constituido por proteínas 
de respuesta a estrés,  chaperonas y proteínas de invasión (HSP 90, HSP 70, HSP ClpB, 
co-chaperona GrpE,  Cpn 20, protein disulfuro isomerasa, proteína 1 de superficie del 
merozoito y antígeno de superficie del merozoito PY230), el segundo por proteínas 
metabólicas (glicerol-3-fosfato deshidrogenasa dependiente de FAD, dihidrolipoamida 
dehidrogenasa, ATP sintase F1 subunidad beta y adenosina desaminasa), y dos 
proteínas hipotéticas. Entre todas las proteínas detectadas, ni las proteínas GrpE y 
Cpn20 ni las cuatro proteínas metabólicas habían sido previamente identificadas como 
inmunogénicas durante la malaria. En este capítulo se discute la posible importancia 
de estas proteínas en la infección su potencial como nuevas dianas para vacunas.  
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1 Summary  
 
Despite more than a century of research efforts to eradicate malaria, the 
disease remains a major, growing threat to the public health and economic 
development of countries in the tropical and subtropical regions of the world. Human 
malaria is caused by infection with intracellular parasites of the genus Plasmodium 
that are transmitted by Anopheles mosquitoes. Of the five species of Plasmodium that 
infect humans, infection with Plasmodium falciparum (P. falciparum) is the most lethal. 
Due to increasing resistance of P. falciparum to anti-malarial drugs and insecticides, 
studies suggest that the number of malaria cases may double in 20 years (WHO, 2007). 
Thus, the discovery of a vaccine against malaria represents an urgent medical need for 
the vast population living in areas where malaria is endemic. The ideal vaccine would 
be cheap, extremely safe, induce life-long immunity, be active against all strains of the 
parasite and result in nearly complete interruption of the malaria life cycle by vaccine-
induced immune responses. While promising results have been obtained, particularly 
with subunit vaccines, progress toward a malaria vaccine has been slow, owing in part 
to extensive genetic diversity in candidate vaccine antigens. In subunit vaccination, 
partial or complete antigens are identified from a pathogen’s proteomic complement 
and used to induce protective immunity to the whole pathogen on vaccination. During 
the life cycle of P. falciparum, several P. falciparum polymorphic antigens are exposed 
to the human immune system. Of these, apical membrane antigen 1 (AMA1), 
merozoite surface protein (MSP-1) and circumsporozoite protein (CSP) are of particular 
interest in vaccine development. Epidemiological data suggest that naturally acquired 
antibodies targeted against merozoite proteins (AMA1 and MSP1) contribute to the 
acquisition of protective immunity in malaria-endemic areas. Thus, although AMA1 
and MSP1 are leading subunit vaccine candidates, their antigenic polymorphism 
continues to thwart vaccine development. 
The human and animal models represented by naturally acquired immunity 
represent powerful models for the development of a vaccine to completely prevent 
infection or to prevent death and severe disease, respectively. However, the specific 
target antigens and epitopes of the protection are largely unknown, and correlates of 
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protection after experimental immunization or natural exposure are unclear. The 
challenge for next generation malaria vaccine is to understand which of the many 
antigen-specific responses might be predominantly responsible for protection, and 
selection of these antigens is in urgent need for vaccine development. 
To achieve this, methodological pathways for the recognition and 
characterization of highly immunogenic antigens need to be developed. Here, in the 
first chapter of this work, we have successfully developed a methodology that could 
permit identification of new antigens exposed during the eritrhocytic stage of the 
parasite. Briefly, by using specificity IgG-binding domains of recombinant protein A/G, 
we have isolated a broad range of IgG subclasses from intact serum obtained from ICR 
mice resistant to the lethal infection by Plasmodium yoelii yoelii 17XL. Purified IgGs, 
were next immobilized covalently onto agarose-loaded spin columns  and the 
assembled columns, were used for isolation of high affinity plasmodial antigens from 
crude parasite extracts obtained from total parasitized infected RBC (iRBC) from 
infected mice. By applying mass spectrometry analysis to the parasite proteins isolated 
by immunoaffinity, we were able to identify 4 plasmodial proteins: i) protein disulfide 
isomerase, ii) a member of the heat shock protein 70 family, iii) plasmepsin and iv) a 39 
kDa-subunit of the eukaryotic translation initiation factor 3. Although we could not 
identify known vaccine target antigens in plasmodium by MS in our immunoaffinity 
eluate, the presence of band patterns in the eluate 1D-electrophoregram possibly 
corresponding to the MSP1 19 kDa subunit and related precursor were observed 
The participation of those identified proteins in partial protective immunity in 
ICR mice population and the new identified ones by their roles to elicit immunity in 
murine model of malaria, is the main part of this study and are presented in details in 
chapter one. Interestingly, the procedure of isolation and identification of parasite 
antigens by using serum IgGs from malaria-protected individuals could be a novel 
strategy for the development of multi-antigen-based vaccine in human, accordingly. 
The second chapter of this study was aimed to examine whether the 
immunoaffinity-isolated parasite antigens were able to induce protective immunity 
against blood stage malaria infection. To examine the hypothesis, two adjuvant 
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formulations were compared in a test vaccine trial: CpG ODN1826 system and Freund´s 
complete (CFA) and incomplete (IFA) system carried out using BALB/c mice strain, 
susceptible to P. yoelii infection. Using a high parasite load on infection, mice treated 
with limiting amounts of antigen mixture using Freund´s system showed some degree 
of protection. Hence, in a second vaccination trial, both the amount of total multiple 
antigens and the number of boosting up were increased to up to 10 µg per each 
inoculation and 3 times, respectively. Western blot analysis of vaccinated mice serum 
at different time post vaccination revealed a broad range of reactivity with total 
plasmodium extracts. Even though all mice have shown strong immune response to 
multiple affinity purified antigens, different levels of protection in vaccinated mice 
challenged by a lethal dose of parasite were observed. Although none of the 
individuals survived the infection, 20% of mice survived more than 14 days and 50% 
survived one more day compared to controls, suggesting some degree of protection 
induced by the antigen mixture used in the test. The comparisons of two vaccination 
trials and analysis of immune response by western blot in each individual vaccinated 
mouse sera at different time post-vaccination and the possible roles of identified 
antigens in protection against lethal Plasmodium infection are dicussed in this chapter. 
As mentioned above, recently accumulated information on malaria vaccine 
studies, have shown many unknown proteins are involved in protection against 
malaria infection. The third chapter of this study, is mainly focused on the 
identification of antigens in blood-stage Plasmodium infection in ICR mice population 
resistant to malaria, by using immunochemical and immunoproteomic approaches. 
Previous work in this laboratory has shown that, upon P. falciparum infection of 
human RBC, both host and parasitic cells suffer significant changes in the pattern of 
protein oxidation. Hence, the identification of potential carbonylated antigens in the 
erythrocyte or the parasite in infected mice, may thus be a valuable strategy for the 
discovery of unknown vaccine antigens. By comparison of 2-D Western blots of total P. 
yoelii protein revealed by using sera from infected ICR mice and, separately, anti-2,4-
dinitrophenylhydrazine (DNPH)  on membranes derivatized after protein transfer, it 
was possible the detection of several carbonylated plasmodial proteins. The coincident 
spots were analyzed by mass spectrometry of triptic digestions, allowing the 
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identification of several proteins belonging to three different classes: fate proteins 
(heat shok protein 90, heat shock protein 70, heat shock protein ClpB, co-chaperone 
GrpE, Cpn 20 protein, protein disulfide isomerase, merozoite surface protein 1 and 
merozoite surface antigen PY230), metabolic proteins (FAD-dependent glycerol-3-
phosphate dehydrogenase, dihydrolipoamide dehydrogenase, ATP synthase F1 subunit 
beta and adenosine deaminase) and two hypothetical proteins. Interestingly, 2 out of 6 
fate protein (co-chaperon GrpE and Cpn20 protein) and all 4 plasmodial metabolic 
enzymes had not been previously identified as immunogenic proteins during blood-
stage malaria infection. The hypothetical roles of the newly identified antigens with 
those already known potential malaria blood-stage vaccine antigens, are discussed in 
this chapter. 
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2 INTRODUCTION 
2.1 Malaria in the world 
Malaria, an infectious disease caused by several apicomplexa Plasmodium 
species, is an important cause of mortality and morbidity in many regions of the world. 
Each year, an estimated 300–500 million people are affected worldwide although the 
true figure may triplicate this number [1]. Malaria kills 1–2 million people each year, 
mostly children under the age of 5 years and a significant number of pregnant women 
in sub-Saharan Africa (WHO The World Health Report Geneva 1999). About half the 
world’s population (3.3 billion) live in areas that have some risk of malaria transmission 
and one fifth (1.2 billion) live in areas with a high risk of malaria (more than 1 reported 
clinical case per 1000 population per year). Another 2.1 billion live in areas of low risk. 
Although low-risk areas cover a large number of people living across a wide 
geographical area, they produce a relatively small number of malaria cases each year 
(less than 2 million) and account for less than 3% of cases reported by countries in 
2006. Africa has the largest number of people living in areas with a high risk of malaria 
followed by the South-East Asia Region (Figure 1). In recent years, there has also been 
an increasing number of malaria cases among travelers to endemic countries. 
 
 
Figure 1. Estimated incidence of clinical malaria per 1000 population. World Malaria Report 2008. 
http://whqlibdoc.who.int/ 
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2.2 Malaria and the Plasmodium life cycle 
 Malaria is caused by unicellular protozoan parasites of the Plasmodium genus. 
There are four species of malaria parasites that infect humans: P. falciparum, P. vivax, 
P. ovale and P. malariae. The most severe form of malaria is caused by P. falciparum. 
The severity of the disease depends largely on the species and strain of the infecting 
parasite, and the immunological status of the infected individual. Cyclical fevers are 
the hallmark of malaria and typically occur shortly before or at the time of red blood 
cell (RBC) lysis as schizonts rupture to release new infectious merozoites. This occurs 
every 48 h in P. vivax, P. ovale and P. falciparum, and every 72 h in P. malariae 
infection Intense fever is accompanied by nausea, headaches and muscular pain, 
amongst other symptoms. In patients infected with P. vivax and P. ovale, relapse may 
recur months to years after initial infection. This is caused by re-activation of the silent 
liver-stage form of the parasites (hypnozoites)[2].  
The disease is transmitted from one infected person to another by the bite of 
female Anopheline mosquitoes. Soon after the female mosquito has ingested blood 
from an infected person, male gametocytes fertilize female gametocytes. Mobile 
products of this fertilization, the ookinetes, burrow through the stomach wall and 
develop into oocysts in the lining of the gut. When the cysts rupture, they release 
sporozoites which enter the salivary glands. Within 60 minutes of inoculation into a 
vertebrate host by the mosquito, the sporozoites move to the liver and invade 
hepatocytes where they remain for 9–16 days and undergo asexual amplification. 
During this pre-erythrocytic stage, the host is asymptomatic [3]. The erythrocytic stage 
begins when the infected liver cell bursts, releasing merozoites into the bloodstream. 
Within 1–2 min of release, each merozoite attaches to specific receptors on the RBC 
membrane via ligands on the surface of the merozoite. Subsequently, the host RBC 
membrane invaginates so that the merozoite moves into the erythrocyte. Residing in 
the parasitophorous vacuole, the parasite undergoes development from the early ring 
stage trophozoite to the late trophozoite and then, after mitotic divisions, to the 
schizont stage, which contains 6–32 merozoites, depending on the parasite species [4] 
. When the erythrocytic schizont ruptures, the merozoites spill into the blood and each 
one continues the life cycle by invading another RBC. During this repeated cycle, a 
small proportion of asexual parasites converts to gametocytes that are essential for 
INTRODUCTION 
9 
transmitting the infection to others through female anopheline mosquitoes, but cause 
no disease [5]. Then the infectious cycle of Plasmodium can repeat itself (Figure 2). It is 
the asexual blood stage that is responsible for the symptoms of the disease. There is 
therefore a significant effort to develop a vaccine against this stage of the life cycle, 
which could limit parasite growth and consequently prevent or minimize clinical 
disease. The successful development of an asexual blood stage vaccine is critically 
dependent upon our understanding of immunity to asexual blood stage parasites [2]. 
 
Figure 2. Malaria life cycle of the Plasmodium parasite has three distinct stages.Malaria sporozoites are 
introduced into humans when an infected female Anopheles mosquito takes a blood meal. (a) During 
the exoerythrocytic stage, sporozoites make their way through the blood to the liver via Kupffer cells (1). 
Sporozoites invade numerous hepatocytes (2) and develop into the exoerythrocytic form (EEF), also 
known as tissue schizonts (3). These EEFs contain many merozoites, which are released and circulate in 
the blood upon EEF rupture (4). (b) The asexual blood stage commences when the merozoite invades a 
red blood cell (RBC; 1). Within the RBC, the merozoite develops into a trophozoite (2) and then into a 
schizont (3). The asexual blood stage cyclically continues as schizonts rupture, releasing merozoites for 
further invasion of RBCs (4 and 1). Male and female gametocytes are also produced during this stage 
and are taken up by the mosquito when feeding (see panel c). (c) The sexual stage takes place within the 
gut of the mosquito. Inside the gut, the gametocytes (1) are released and fuse to form a zygote (2), 
which in turn develops into an ookinete (3). The ookinete crosses the midgut epithelial cell wall. 
Between the epithelial cell wall and the basal lamina of the midgut, the ookinete develops into an 
oocyst (4). The oocyst produces thousands of sporozoites, which are released into the hemocele (the 
body cavity) and are carried in the hemolymph to the salivary glands (5), ready for injection into the 
next host. (Adapted from [6]) 
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2.3 Plasmodium parasites and mice models 
Four species of murine parasites are available to model human malaria: P. 
chabaudi, P. berghei, Plasmodium vinckei and P. yoelii. Among them, P. chabaudi 
provides an excellent experimental tool with many similarities to P. falciparum. The 
sequencing of the genomes of both P.falciparum and P.chabaudi is facilitating 
comparative analysis of antigens that may be important in understanding the 
immunobiology of malaria, as well as offering novel candidate vaccine targets [7].  
These include analogous blood-stage antigens, invasion of immature and mature 
erythrocytes, suppression of B- and T-cell responses, and parasite sequestration in liver 
and spleen [8]. In this infection model, a rapid multiplication of the parasite during the 
first week post infection (pi) is followed by a curative phase in resistant mice with 
immune and erythropoietic responses, eliminating the parasites by the fourth week pi. 
Susceptible animals lack these responses and usually die during the second week pi. 
Two subspecies of P. chabaudi have been defined: P. chabaudi chabaudi and P. 
chabaudi adami. Both have been extensively used to study the immunological basis of 
some of the pathologies of human malaria and in genetic linkage studies to map loci 
controlling parasitic levels. P. berghei is a useful experimental model of cerebral 
malaria. P. yoelii is the third most common parasite in mouse malaria studies. There 
are three recognized subspecies: P. yoelii yoelii, P.yoelii killicki and P. yoelii nigeriensis. 
Most of them have been widely used as models for the development and 
characterization of vaccine candidates, in the investigation of red blood cell invasion 
and, more recently, in genetic linkage studies. The least studied of the parasite P. 
vinckei is, however, the most widely distributed of the murine species. Four subspecies 
are recognized: P. vinckei vinckei, P. vinckei petteri, P. vinckei lentum and P. vinckei 
brucechwatti. P. vinckei vinckei and P. vinckei petteri have been used in several 
chemotherapeutical studies and in the identification of new antimalarial drug targets 
[8].  
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Table 1. Plasmodium infections in different strains of mice. BALB/c mice can be susceptible or resistant 
to Experimental Cerebral Malaria (ECM) caused by P.berghei ANKA depending on the sourse.  L letal, NL 
non-lethal. (Adapted from [9]. 
 
Parasite Strain Mouse strain Lethality Experimental use 
P. chabaudi 
chabaudi 
 CBA 
C57BL/6 
BALB/C 
NL Immune mechanisms 
Malaria associated clinical 
signs/sequestration 
P. chabaudi 
chabaudi 
AS 129sv 
A/J 
DBA/2 
L Pathogenesis  
Chemotherapy 
Resistance and susceptibility 
Immune mechanisms 
P. chabaudi 
chabaudi 
CB CBA 
C57BL/6 
L Pathogenesis  
Chemotherapy 
Resistance and susceptibility 
Immune mechanisms 
P. chabaudi adami  BALB/c 
C57BL/6 
NL Immune mechanisms 
P. berghei ANKA BALB/c 
C57BL/6 
CBA 
L Pathogenesis 
ECM/sequestration 
P. berghei K173 BALB/c 
CBA 
DBA 
C57BL/6 
L Pathogenesis 
Control for ECM 
 
P. yoelii 17XL CBA 
BALB/c 
C57BL/6 
DBA 
 
Swiss 
L 
 
 
 
 
L 
Immune mechanisms 
 
 
 
Pathogenesis 
ECM/sequestration 
P. yoelii YM CBA 
BALB/c 
C57BL/6 
DBA 
L Vaccine 
Pathogenesis 
Hypoglycaemia 
P. yoelii 17XNL CBA 
BALB/C 
C57BL/6 
DBA 
NL Immune response 
Vaccination 
Immune mechanisms 
P. vinckei vinckei  BALB/c L Chemotherapy 
Pathogenesis 
Malaria associated clinical 
sign/sequestration 
P. vinkei petteri CR C57BL/6 
BALB/c 
NL Immune mechanisms 
 
 
2.4 Malaria and the immune response 
In populations continuously exposed to malaria, several types or levels of 
immunity against P. falciparum co-exist. Immunity to severe clinical episodes (including 
cerebral malaria, severe anaemia, metabolic acidosis, and other severe manifestations) 
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is observed in older children and adults, is acquired relatively early (usually complete 
by the age of five years), and lasts for life [10, 11]. Immunity to mild clinical episodes 
takes longer to establish. Young adults remain susceptible often until their middle to 
late twenties. Sterile immunity to infection with parasites is rarely, if ever, observed. 
The prevalence of P. falciparum parasitaemia increases steeply in early childhood, 
remaining high for a period of time after, immunity to severe and mild disease is well 
established. Thus, the expression of the acquisition of immunity appears to be 
sequential, with the ability to limit parasite growth and multiplication, followed by 
essentially complete protection against severe and then mild clinical disease, and 
culminating with partial protection against infection. Both innate [12] and acquired 
immunity [13] appear to take place in human and in rodent models, involving antibody 
and cell-mediated processes. 
 
2.4.1 Antibody-mediated immunity to asexual blood stage malaria 
It is well established that B cells and Ab play a crucial role in immunity to 
malaria. It has been demonstrated that naturally acquired immunity to malaria in 
individuals living in endemic areas, which takes several years to develop, is thought to 
be largely dependent largely on the acquisition of a repertoire of specific, protective 
Ab directed against several polymorphic target antigens. The unequivocal 
identification of such antigens has not been, however, feasible. The best protective 
antigen so far proposed, P. falciparum erythrocyte membrane protein-1 PfEMP-1 [14], 
has been associated with protection in some studies, but not in others [15-23]. 
Treatment of P. falciparum infected Thai patients with IgG extracted from immune 
African adults resulted in reduction of parasite load and clinical symptoms [24]. In 
mice, passive transfer of monoclonal Ab (mAb) against parasite antigens confers 
protection in naive mice [25, 26]. Immunoglobulin (Ig) μ-chain gene-targeted (μ-MT) 
mice lacking B cells are unable to clear parasites from P. chabaudi chabaudi AS 
infection, and instead develop chronic parasitaemia [27, 28]. Infected μ-MT mice 
treated with antimalarial drugs develop acute parasitaemia during secondary infection 
that resembles a primary infection, although with a reduced parasite density [28] and 
the subsequent chronic infection is not resolved, indicating that B cells are required for 
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development of protective immunity. Adoptive transfer of B cells from immune donors 
at a later stage of infection restores the ability of deficient mice to complete parasite 
clearance, confirming the critical role of B cells in the clearance of blood stage 
parasites [28]. Studies in B-cell deficient mice demonstrate that B cells also play an 
essential role in switching from a Th1 response to a Th2 response, which is critical for 
the complete resolution of P. chabaudi infection [27]. The degree of protective 
immunity in humans [29], monkeys [30] and mice [31, 32] has been shown to correlate 
with the level of Ab against asexual blood stage antigens, and is dependent on Ab 
isotypes. The IgG subclass responses against ring-infected erythrocyte surface antigen 
(RESA), merozoite surface protein (MSP) 1, MSP-2 and crude [33] P. falciparum antigen 
in people living in exposed areas are partly determined by host genetic factors and are 
age dependent. Cytophilic Ab of the IgG1 and IgG3 subclasses are considered to be the 
most important Ab for protection against P. falciparum malaria in humans [33]. Acting 
in collaboration with effector cells such as monocytes and macrophages, they mediate 
opsonization and Ab-dependent cellular inhibition. A seroepidemiological study has 
shown that increased levels of P. falciparum-specific IgG1 and IgG3 in individuals living 
in endemic areas are associated with lower parasitaemia and reduced risk of malaria 
pathology [34, 35]. 
Protection attributable to parasite-specific IgG3 is age-associated, with greater 
levels of protection seen in adults. In addition to IgG1 and IgG3, IgG2 may be involved 
in protection. High levels of IgG2 to RESA and to MSP2 are associated with resistance 
to P. falciparum at the end of the transmission season and levels tend to be higher in 
older individuals who are better protected against infection and disease [36]. In 
contrast, levels of IgG4 to parasite extract, RESA, MSP1 and MSP2 are lower in 
individuals who do not develop malaria than in susceptible individuals and are 
positively correlated with risk of infection. It has been suggested that IgG4 competes 
with cytophilic Ab for antigen recognition and may therefore block cytotoxicity 
mediated by Ab activated effector cells [36].  
From a mouse model, Jayawardena et al. [37, 38] demonstrated that the 
passive transfer of hyperimmune serum to CBA mice completely protected them 
against challenged with 104 P. yoelii 17XNL-parasitized erythrocytes. In addition, 
passively transferred antibodies (Ab) delayed the onset of infection when larger 
 INTRODUCTION 
14 
 
inocula (5 × 104 or 1 × 105 PRBC) were used [38]. Similar results have been reported for 
BALB/c mice [39]. A heterogenous Ab response is induced by P. yoelii. Langhorne et al. 
investigated the antimalarial Ab response to P. yoelii 17XNL in C3H mice and found 
that immunoglobulin M (IgM), IgG1, IgG2, and IgG3 Ab were produced, with the 
highest titers being of the IgG2 isotype [40]. 
In mice, the cytophilic isotype, IgG2a, is associated with protection against 
Plasmodium infection [41, 42]. IgG2a is predominant during the primary ascending 
parasitaemia in mice infected with P. chabaudi AS followed by an IgG1 response during 
the chronic stage of infection, as a consequence of Th1 to Th2 switching [43]. It has 
been shown that IgG1 and IgG2b can confer protection against lethal challenge 
infection with P. yoelii YM in mice immunized with MSP119 [31]. IgG3 may also be 
important, as passive transfer of anti-MSP119 IgG3 into naive recipients resolves P. 
yoelii infection [44, 45]. Antibody responses directed against surface proteins of the 
merozoite may function either by blocking RBC invasion or by making the merozoite 
susceptible to phagocytosis. Parasite antigen-specific Ab play an important role in 
controlling parasitaemia via Ab-dependent cellular inhibition (ADCI), whereby binding 
of antibodies to phagocytes via Fc receptors leads to inhibition of parasite growth [24, 
36, 46, 47]. It has been demonstrated that specific Ab initiate parasite clearance by 
opsonization, thus enhancing the activity of phagocytic cells [48] or initiating 
complement-mediated damage [49, 50].  
Despite the importance of Ab responses for protection against malaria, it seems 
that not all Ab are protective. Polyclonal Ab specific to MSP2, but not mAb specific to 
the same antigen, enhance invasion of multiple merozoites into RBC [51, 52]. 
Furthermore, these MSP2-specific Ab at high-titre fail to induce complement-mediated 
damage. In another example, mAb against MSP119 which inhibit RBC invasion by 
merozoites and prevent MSP-1 secondary processing, can be blocked by other mAb to 
the same antigen [53]. These studies illustrate the importance of identifying epitopes 
that induce protective Ab when designing a vaccine against malaria. 
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2.4.2 Cell-mediated immunity and malaria 
CD4 T cells are classified into two major subsets according to their pattern of 
cytokine production. Th1 cells produce interleukin (IL)-2, interferon (IFN) γ, and 
tumour necrosis factor, whereas Th2 cells produce IL-4, IL-5, IL-6 and IL-10 [54]. In 
general, Th1 cells are responsible for cell-mediated immunity (CMI). They activate 
macrophages and other cells to produce mediators through the release of 
inflammatory cytokines. In Th1 cytokines, IFN γ has been shown to be associated with 
clearance and protective immunity in malaria [55-61]. Th1 cells enhance the 
production of Ab that promote opsonization and phagocytosis, mainly IgG2a and IgG3 
in mice, and IgG1 and IgG3 in humans. Th2 cells regulate humoral immunity by 
providing help to B cells for the production of Ab. Th2 cells promote the production of 
IgG subtypes that are associated with allergies and helminthic infections, such as IgG1 
in mice and IgG4 in humans. However, considerably less is known about the Th2 
response and the role of Th2 cytokines in malaria disease. 
 
2.4.3 Mediators of cell-mediated immunity to malaria 
Interleukin-12 is a key cytokine that initiates Th1 responses by triggering IFNγ 
production from natural killer (NK) and CD4 T cells [62]. Interleukin-12 secretion is 
induced by various infectious agents, including viruses, bacteria and parasites. During 
malaria infection, early non-specific immune responses can be augmented by the 
release of IL-12 from splenic macrophages [63, 64]. Administration of anti IL-12 Ab to 
normal mice during P. berghei infection results in a marked reduction of IFNγ 
production, showing that IL-12 is a potent inducer of IFNγ during malaria infection [65]. 
Treatment of P.  chabaudi AS susceptible A/J mice with IL-12 results in increased 
numbers of NK cells which spontaneously secrete IFNγ and TNFα [66]. Consequently, 
IL-12 treated A/J mice are able to eliminate parasites and survive infection, whereas 
untreated A/J mice develop high parasitaemia and die. The ability of mice to control 
parasite growth is abrogated when the mice are depleted of NK cells, indicating that 
the protective effects of IL-12 are mediated by NK cells [66, 67]. In addition to 
activation of NK cells, IL-12 enhances production of IFNγ by CD4 T cells, which is also 
critical for protection [68]. Taken together, the data indicate that IL-12 plays an 
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important role in protective immunity to blood stage malaria by inducing IFNγ 
production by NK and CD4 T cells. In the mouse model, infection of IFNγ-deficient mice 
with P. c. chabaudi AS results in increased morbidity and mortality, [69, 70] indicating a 
role for this cytokine in protection. 
Recruitment and local proliferation of macrophages are also impaired in the 
absence of IFNγ [69]. Mice defective in IFNγ and its receptor show a predominantly 
Th2 response, which is associated with susceptibility to P. chabaudi infection [69, 71]. 
Thus, IFNγ is critical for resistance to blood stage malaria, through the stimulation of 
cytokine production by effector cells and enhanced activity of macrophages. Tumour 
necrosis factor α production is greatly augmented during malaria infection, as shown 
by elevated levels of TNFα in plasma of patients with malaria [72, 73] and infected 
mice [67, 74]. As well as being induced by cytokines such as IFNγ, [69] TNFα release by 
macrophages can also be directly induced by malaria parasites and their soluble 
antigens, such as malaria pigment (haemozoin) [75] and glycosylphosphatidylinositols 
[76]. High levels of TNFα mRNA expression in the spleens of C57BL/6 mice correlate 
with resistance to P. chabaudi AS infection, and administration of anti-TNFα Ab to 
resistant mice abrogates the immunity, indicating a protective role for TNFα [77]. 
Mouse sera containing TNFα inhibit growth of P. falciparum in vitro by causing 
deterioration and degradation of parasites, suggesting that TNFα has a non-specific 
inhibitory effect on the parasites [78, 79]. Collectively, the data demonstrate that cell-
mediated immunity can be beneficial or detrimental to the malaria infected host. To 
achieve desirable outcomes, the balance of mediators that are involved in the immune 
response to malaria must be tightly controlled. An understanding of the mechanisms 
by which cytokines induce protection and/or pathology in malaria will prove to be 
fundamental for designing vaccines and developing new therapies for malaria.  
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Figure 3.  Linking Innate and Adaptive Immunity to Blood-Stage Malaria Possible regulation of adaptive 
immunity to bloodstage malaria by cytokines produced by cells of the innate immune response. In 
response to parasite ligands recognized by pattern-recognition receptors (PRRs), such as Toll-like 
receptors (TLRs) and CD36, or inflammatory cytokines, such as interferon- (IFN-), dendritic cells (DCs) 
mature and migrate to the spleen—the primary site of immune responses against blood-stage 
Plasmodium parasites. Maturation of DCs is associated with the upregulation of expression of MHC class 
II molecules, CD40, CD80, CD86, and adhesion molecules and the production of cytokines including 
interleukin-12. IL-12 activates natural killer (NK) cells to produce IFN- and induces the differentiation of 
Th1 cells. The production of cytokines, particularly IFN-, by NK cells results in DC maturation and 
enhances the effect of parasite-derived maturation stimuli, facilitating the clonal expansion of antigen-
specific naive CD4+ T cells. IL-2 produced by antigen-specific Th1 cells further activates NK cells to 
produce IFN, which induces DC maturation and activates macrophages, further amplifying the adaptive 
immune response. Cytokines such as IL-10 and transforming growth factor-β (TGF-β) negatively regulate 
both innate and adaptive responses. NO, nitric oxide; TCR, T cell receptor; TNF, tumor-necrosis factor. 
(Adapted from [80]). 
 
2.5 Selection of antigens for blood stage malaria vaccine 
Since clinical symptoms of malaria manifest only during the blood stage, a 
vaccine against this stage of the parasite life cycle would prevent or reduce severity 
and complications of the disease, and perhaps eliminate malaria if sterile immunity 
could be achieved. In red cells, parasites appear well located to avoid host responses. 
Red cells lack class I and class II MHC molecules and antigen-processing machinery. 
Therefore, direct T cell-mediated responses are not induced to determinants 
presented at the host cell surface. Only at schizont rupture is the parasite directly 
exposed, when, for a very brief period, daughter merozoites have to attach to and 
enter new red cells. Much attention has therefore been given to parasite molecules 
that interact with the host cells during RBC invasion as potential targets of host 
immune responses. A number of proteins have been identified on the merozoite 
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surface or in the apical organelles that play a role in RBC invasion and are thought to 
be targets of immunity. 
 
1.5.1 Merozoite surface proteins 
Among these molecules merozoite surface proteins are potential malaria 
vaccine candidates as they play important roles in the initial recognition and 
attachment of merozoites to the RBC surface [81-84]. As proteins on the merozoite 
surface are exposed to the host immune system, they are thought to be targets of 
immune response [85, 86]. Merozoite surface protein 1 is a glycoprotein synthesized as 
a high molecular weight ( 1̴85–205 kDa) precursor protein [87-89]. The protein 
precursor is processed at least twice by protease enzymes into a number of fragments. 
At schizont rupture, primary processing occurs, giving rise to major fragments of 
approximately 83 (MSP183), 28–30 (MSP130), 38 (MSP138) and 42 (MSP142) kDa found 
as a non-covalently associated complex held together on the free merozoite surface by 
the 42 kDa fragment [87-89] (Figure 4).  At the time of merozoite invasion, secondary 
processing, which is a prerequisite for RBC invasion, takes place [90]. 
Epidemiological studies in malaria endemic areas show that PfMSP-119 
seropositive children are significantly more resistant to clinical malaria than 
seronegative children [18, 19]. In the same study, human antibodies to PfMSP-119, 
acquired in response to natural infection, inhibited merozoite invasion of erythrocytes. 
Since this study was conducted using affinity-purified antibodies, inhibition did not 
require the presence of either complement or mononuclear cells, occurred at 
physiological antibody concentrations and was equally effective against parasites 
expressing both major sequence variants of PfMSP-119 [91].    
However the epidemiological evidence of the protective effect of naturally 
acquired anti-merozoite responses has not been clearly stablished in malaria endemic 
populations [22]. In a recent study conducting a Meta-analysis Of Observational 
Studies in Spidemiology (MOOSE), some support for the protective effect of total IgG 
responses to particular merozoite surface antigens against symptomatic P.falciparum 
malaria has been found in human asindividuals having  IgG against MSP-3-Ct and MSP-
119 appeared to have a lower risk (54% and 18%, respectively) of symptomatic P. 
falciparum infection as compared to individuals . that iswithout detectable IgG.[92] 
INTRODUCTION 
19 
 
The whole molecule of MSP1 has been shown to induce protection against lethal P. 
yoelii YM and P. falciparum in mice and monkeys, respectively [93, 94]. 
 
 
 
 
Figure 4. Schematic showing processing of merozoite surface protein 1 (MSP1)(modified from Blackman 
et al. [95]) Panel (A) shows primary processing, and (B) shows secondary processing. (Adapted from [2]).  
 
 Immunization of mice with the C-terminal proteins, MSP119 and MSP142, 
induces protection against P. yoelii infection [96] and passive transfer of mAb specific 
to MSP119 or MSP142 suppresses parasitaemia [26], indicating that MSP119 and MSP142 
also play an important role in protective immunity. 
 
1.5.2 Apical Merozoite surface antigen 1 
Apical merozoite surface antigen 1 (AMA1) is an integral membrane protein 
located in the apical secretory organells or rhoptries, of developing and free 
merozoites. AMA1 has been found in all Plasmodium species studied and is a target of 
antibodies that neutralize invasion of erythrocytes [97, 98]. Protective immune 
responses induced by AMA1 have been shown in mice [99, 100] and monkeys [101, 
102]. Although the specific function of AMA1 during merozoite invasion is unknown, 
PyAMA1 has been identified as an erythrocyte binding protein, and MAb 45B1 against 
PyAMA1 blocks this ligand-receptor interaction [103]. Native PyAMA1 induces a 
protective response, and passive immunization with MAb 45B1 protects against a 
lethal blood-stage infection with the YM line of P.yoelii [25].  
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1.5.3 High-molecular-mass rhoptry proteins 
Another target of antibodies that protect against the virulent YM parasite is the 
family of high-molecular-mass rhoptry proteins (PyP235) [93, 104]. PyP235 is coded by 
a multigene family [105, 106], and at least one of the PyP235 proteins binds to the 
surface of mouse erythrocytes [107, 108], suggesting that they are involved in 
erythrocyte recognition and invasion. PyP235 proteins are members of a superfamily 
that includes reticulocyte binding proteins of P. vivax [109] and proteins recently 
identified in P. falciparum [110-112]. Immunization with PyP235, or passive 
immunization with two MAbs (25.77 and 25.37) directed against PyP235, protects 
BALB/c mice against challenge with the virulent P.yoelii YM line [93, 104], restricting 
the parasite to reticulocytes. PyP235 binds preferentially to mature erythrocytes, and 
the binding is inhibited by specific antibodies, suggesting a role in the invasion of 
mature erythrocytes but not reticulocytes [113]. Distinct subsets of Py235 are 
expressed in sporozoite, hepatic merozoites and erythrocytic merozoites [114] 
indicating a conserved role of Py235 in the invasion of different host cell populations. 
 
2.6 Malaria vaccines 
Although an increased number of tools for the control of malaria are now 
available, the majority of these are at best, partially effective and require substantial 
training and resources to implement at national levels [115]. Many malaria control 
experts argue that effective vaccination against malaria is in fact, the only realistic 
long-term solution for resource-poor countries [116]. To date, in spite of many years of 
dedicated and high quality research, there is still no effective malaria vaccine, although 
the continous progress makes reasonable to expect some succes in the short-to 
medium term. Most efforts to develop a malaria vaccine are focused on P. falciparum 
as it is responsible the most severe forms of the disease. The belief that it will be 
possible to develop an effective vaccine for malaria stems from three principal 
observations. First, complete protection against experimental sporozoite challenge has 
been achieved in rodents [117], non-human primates [118] and humans [119, 120]. 
Second, individuals living in endemic areas naturally acquire non-sterile immunity to 
malaria in which they are protected from severe illness and death, while remaining 
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susceptible to infection [10]. Third, in classic experiments, passively transferred 
antibodies from malaria ‘immune’ individuals were effectively used to treat both 
children and adults with severe malaria [121, 122]. Two main strategies for malaria 
vaccine development are currently being pursued, largely in parallel: the sub-unit 
approach and the whole-organism approach. 
 
1.6.1. Sub-unit Vaccines 
The rationale behind these vaccines includes the ability to block the molecular 
interactions (eg. receptor-ligand binding) that are known to occur between the host 
and parasite, for example, during invasion of hepatocytes and erythrocytes by 
sporozoites and merozoites, respectively. It also includes the ability of single antigens 
to induce protective cell- or antibody-mediated immune responses. For example, 
antibodies that block the binding of merozoite surface proteins which mediate 
invasion of red blood cells could halt the proliferation of blood stage parasites, thereby 
preventing disease. Sub-unit vaccines can be made up of single or multiple antigens, 
and can target a single stage of parasite development or target multiple stages. 
Alternatively, they can be designed as multi-epitope vaccines, containing a string of 
immuno-dominant epitopes from a combination of antigens. Stage-specific vaccines 
can be classified as pre-erythrocytic, erythrocytic and sexual-stage based on the 
antigens they contain. 
Of all the sub-unit pre-erythrocytic vaccine candidates currently under 
development, the one based on the CSP has shown some encouraging results. In the 
RTS,S/AS02 vaccine, the central tandem (asparagine-alanine-asparagine-proline, 
NANP) repeat and carboxy-terminal regions of CSP are fused to the S antigen of 
hepatitis B virus (HBsAg) and co-expressed in yeast with un-fused HBsAg. The resulting 
complex is formulated with the adjuvant AS02 (GlaxoSmithKline Biologicals) which 
contains an oil-in-water emulsion and immuno-stimulants. In phase IIa trials, RTS,S had 
a protective efficacy of 41% (95% confidence interval (CI) 22-56%, p = 0.0006) against 
experimental sporozoite challenge of malaria-naïve volunteers [123]. In a phase IIb 
trial in Gambian adults, it had a modest protective efficacy against time to first 
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infection of 34% (95% CI 8-53%), though this protection appeared to be short-lived 
[124]. In African children however, the results of both phase I and IIb trials have been 
incrementally encouraging. In this population, RTS,S has been shown to be safe, well-
tolerated and immunogenic both in older children aged 1-4 years [125-128] and in 
infants [129]. Although its reported vaccine efficacy against clinical disease has been 
modest (30-35%), its protective efficacy against severe disease has been substantial 
and sustained, 58% (95% CI 16-81%) at 6 months, 49% (95% CI 12-71%) at 18 months 
[125, 130]. 
Some are skeptical about RTS,S, in part because its precise mechanism of action 
remains unclear [131, 132]. While there is evidence that it induces high levels of IFN-γ 
producing CD8+ (non-cytolytic) and CD4+ T cells, as well as antibodies, particularly in 
the presence of key adjuvants, these immune responses have not consistently 
correlated with protection [133, 134]. Others have shown using transgenic parasites 
that sterile protection against malaria can be obtained independently of immune 
responses to CSP. Mice immunized with irradiated wild type P. berghei were 
completely protected against challenge with parasites in which P. berghei CSP had 
been replaced with that of P. falciparum, a result which could not be accounted for by 
cross-reactivity of responses to CSP [135]. From a separate viewpoint, unlike other 
malaria vaccine candidates, there is little evidence that immune pressure from the 
human host has driven the polymorphisms observed in CSP in natural infections [136, 
137], neither is there evidence that RTS,S-induced immune responses select for 
parasites bearing divergent CSP alleles (as opposed to those contained in the vaccine) 
as might have been anticipated [138]. 
With regard to erythrocytic stage vaccines, the furthest along the line of 
vaccine development are based on MSP-1, -2, -3, apical membrane antigen 1 (AMA-1) 
and glutamate rich protein (GLURP) [139]. The first field trial of an asexual blood-stage 
vaccine was that of the Combination B vaccine, which contains MSP-1 (a 175 amino 
acid fragment from the relatively conserved blocks 3 and 4 of the K1 parasite line), 
MSP-2 (the 3D7 allelic type, nearly full length protein), CSP (a T cell epitope), and the 
ring-infected erythrocyte surface antigen (RESA, containing 70% of the native protein 
from the C terminal end of the molecule). In a phase 1-2b trial, 120 children in Papua 
INTRODUCTION 
23 
 
New Guinea were randomized to receive either vaccine or placebo. The 60 children in 
each arm were further randomized into two equal groups, one with pre-treatment 
with sulphadoxine-pyrimethamine (SP) to clear parasites at the start of the study (n= 
30), and the other to no-SP treatment (n=30). Although this vaccine had no effect on 
clinical disease, parasite densities were lower in the vaccine group compared to the 
placebo group (vaccine efficacy 62% (95% CI 13 – 84)), but only in children who were 
not pre-treated with SP (n=30). Based on these results, the authors concluded that the 
MSP-2 component of the vaccine had a specific effect on parasite growth and 
multiplication, and moreover had induced selection pressure on the parasites [140]. In 
the same study, high 3D7-specific antibody titres were obtained post vaccination in 
both the SP and No-SP pre-treatment groups, casting doubt on the mechanism by 
which vaccine-induced antibodies reduced parasite densities only in the latter group 
[141]. Although widely quoted, this combination B vaccine study provides remarkably 
weak evidence in support of arguments to include the major allelic types of antigens in 
blood-stage malaria vaccines. 
In contrast to the pre-erythrocytic and erythrocytic stages, sexual-stage 
vaccines aim to block malaria transmission from infected hosts, thereby providing a 
herd benefit for future exposed populations. Studies on two leading candidates for 
malaria transmission blocking vaccines in humans have been conducted for Pfs25 and 
Pvs25 proteins expressed on the surface of ookinetes in the mosquito stage of 
P.falciparum and P.vivax, respectively [142], where vaccine induced antibodies to 
Pvs25 (a protein found on the surface of ookinetes) induced significant transmission 
blocking activity as detected by the membrane feeding assay [143]. 
Vaccines combining several key antigens from multiple stages would have the 
potential to interrupt the life cycle of the parasite at multiple points. In a multi-
antigen, multi-stage vaccine for instance, parasites that survived the range of immune 
responses induced by pre-erythocytic antigens, would then have to contend with those 
induced by blood stage antigens. The different antigens could be selected to target 
discrete pathways essential to parasite survival within each stage, and ideally induce 
both antibody- and cell-mediated immunity. In addition, the antigens could be 
sufficiently diverse to overcome the genetic restriction of the host immune response 
 INTRODUCTION 
24 
 
and polymorphism of critical target epitopes. While attractive conceptually, few 
human trials with multi-stage, multi-component vaccines have actually been 
performed. The first synthetic malaria vaccine (SPf66) to be tested in malaria-endemic 
areas contained multiple components from both the pre-erythrocytic and erythrocytic 
stages of P. falciparum [144]. Despite initial promise, a recent meta-analysis of ten 
trials conducted in malaria-endemic areas found no evidence of protection conferred 
by vaccination with SPf66 [145]. Of the many lessons that could be learned from the 
‘failure’ of Spf66 [146], perhaps the most important is the need to understand the 
mechanism(s) by which future vaccines exert their anti-malarial effects. Improvements 
to Spf66 were precluded in part, by a lack of understanding of its mode of action [147]. 
Vaccine induced total IgG antibodies to Spf66 did not correlate with the ability of sera 
to inhibit growth, or with partial clinical protection [148]. In a separate attempt, 
vaccination with NYVAC-Pf7, a pox-vectored malaria vaccine that contained seven 
antigens from all three stages of the parasite life cycle within the human host (CSP, 
PfSSP2, LSA1, SERA, AMA1, Pfs25), also yielded disappointing results when volunteers 
were challenged [149]. 
 
1.6.2. Whole-organism vaccines 
The whole organism vaccine approach shares the same foundations as the pre-
erythrocytic vaccines: the demonstration of sterile immunity following immunization 
with radiation-attenuated sporozoites. Volunteers were infected with P. falciparum 
and were treated with doses of chloroquine sufficient to suppress but not eradicate 
the parasites. Gametocytes were allowed to develop and then mosquitoes were fed on 
the volunteers [119]. This approach was simplified with the advent of methods to 
culture P. falciparum in vitro [150], produce gametocytes in culture (Campbell, Collins 
et al. 1982) and infect mosquitoes from in vitro gametocyte cultures [151]. More 
recent studies have confirmed that the method works in principle, but requires 1000 
or more infective mosquito bites, making it logistically impractical to implement on a 
large-scale [120]. 
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An alternative strategy for the whole organism approach is the use of 
genetically-attenuated parasites. In place of radiation, genetic engineering is used to 
attenuate sporozoites such that they remain viable, are able to infect hepatocytes, but 
unable to develop into mature pre-erythrocytic forms. Importantly, this can be 
reproduced consistently and in a standardized fashion. In a mouse model infected with 
P. berghei, inactivation of liver-stage specific genes, UIS3 and UIS4 (up-regulated in 
infective sporozoites) or the sporozoite-specific gene P36p, render parasites incapable 
of completing their intra-hepatic development, but induce immune responses that 
confer sterile protection when challenged with wild type infectious sporozoites [152, 
153]. 
 
2.7 Malaria and vaccine adjuvants 
Adjuvants are molecules, compounds or macromolecular complexes that boost 
the potency and longevity of specific immune response to antigens, but cause minimal 
toxicity or long lasting immune effects on their own [154]. The addition of adjuvants to 
vaccine enhances, sustains and directs the immunogenicity of antigens, effectively 
modulating appropriate immune responses, reducing the amount of antigen or 
number of immunization required and improving the efficacy of vaccines in newborns, 
elderly or immune-compromised individuals [155].  
It is generally accepted that subunit vaccines for malaria will require adjuvants 
to induce protective immune responses, and availability of suitable adjuvants has in 
the past been a barrier to the development of malaria vaccines. Several novel 
adjuvants are now in licensed products or in late stage clinical development, while 
several others are in the earlier development pipline [156]. Successful vaccine 
development requires knowing which adjuvants to use and knowing how to formulate 
adjuvants and antigens to achieve stable, safe and immunogenic vaccines [156].  
Adjuvants can be classified according to their component sources, physiochemical 
properties or mechanisms of action [156, 157]. Two classes of adjuvants commonly 
found in modern vaccines include: 
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i) Immunostimulants (Table 2) that directly act on the immune system to 
increase responses to antigens. Examples include: TRL ligands, cytokine, 
saponins and bacterial exotoxine that stimulate immune responses. 
Table 2. Immune response triggered by immunostimulants. (Adapted from [157]). 
Immunostimulant Cellular interaction Type of immune response 
TRL ligands   
Bacterial lipopeptide, lipoprotein and 
lipoteichoic acid; mycobacterial 
lipoglycan; yeast zymosan, porin 
TLR-2, 1/2 , 2/6 Th1,antibody (Ab), NK cell 
Viral double stranded RNA TLR-3 NK cell 
Lipopolysaccharide, Lipid A, 
monophosphoryl lipid A (MPL®), AGPs 
TLR-4 Strong Th1,Ab 
Flagellin TLR-5 Th1, CTL, Ab 
Viral single stranded RNA, 
imidazoquinolines 
TLR-7/8 Strong Th1, CTL 
Bacterial DNA, CpG DNA, hemozoin TLR-9 Strong Th1, CTL and Ab; NK cell 
Uropathogenic bacteria, protozoan 
profilin 
TLR-11 Th1 
Others   
Saponins (Quil-A, QS-21, Tomatine, 
ISCOM, ISCOMATRIXTM) 
Antigen processing Strong Th1, CTL and Ab; long 
term memory 
Cytokines: GM-CSF, IL-2, INF-γ, Flt-3. Cytokine receptors Th1, Ab 
Bacterial toxins (CT, LT) ADP ribosylating factors Ab 
 
ii) Vehicles (Table 3) that present vaccine antigens to the immune system in an 
optimal manner, including controlled release and depot delivery systems to 
increase the specific immune response to the antigen. The vehicle can also 
serve to deliver the immunostimulants described in the previous point. 
Examples include: mineral salts, emulsions, liposomes, virosomes 
(nanoparticles made of viral proteins such as influenza hemagglutinin and 
phospholipids), biodegradable polymer microspheres and so-called immune 
stimulating complex. 
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Table 3. Immune response triggered by vehicle or delivery system. (Adapted from [157]). 
 
Vehicle or delivery systems 
Type of immune response 
Th1 Th2 Cross 
primming 
B-cell Mucosal Persistent 
T-and B-
cell 
       
Mineral Salts (aluminium salts, 
calcium phosphate, AS04 
[Alum+MPL®] 
+ ++ - +++ - + 
Emulsions [MF59TM(squalene/water), 
QS21,AS02(squalene+MPL®+QS21), 
IFA, Montanide®, ISA51, Montanide®, 
ISA720] 
++ - - +++ - - 
Liposomes(DMPC/Chol, AS01) +++  + + - ++ 
Virosomes(IRIV), ISCOMs ++ ++ ++ +++ - - 
DC Chol, mineral oil, IFA, Montanide®, 
squalene 
- ++ - +++ - - 
Mucosal delivery systems:Chitosan - - - - - ++ 
Microspheres + - ++  - - 
 
2.7.1 Freund`s adjuvant 
For half a century, incomplete (IFA) and complete Freund´s adjuvant (CFA) have 
been the most commonly used immunoadjuvants for experimental work [158]. It is 
generally assumed that incomplete (IFA) and complete Freund´s adjuvant (CFA) act by 
prolonging the lifetime of injected antigens, by stimulating its effective delivery to the 
immune system and by providing a complex set of signals to the innate compartment 
of the immune system, resulting in altered leukocyte proliferation and differentiation. 
 Freund had suggested three categories of action mechanisms: 1) prolongation 
of the presence of antigens at the site of injection, 2) more effective transport of the 
antigens to the lymphatic system and to the lungs, where the adjuvant promotes the 
accumulation of cells concerned with the immune response, and 3) other mechanisms 
that should remain unidentified, because their clarification would require knowledge 
about how antibodies are formed and how sensitization develops. Briefly, later studies 
on some mechanisms of action for Freund´s adjuvant were categorized as follows; i. 
Enhancment of antigen uptake by APCs, ii. Emission of danger signals resulting in Th1 
skewing, iii. Cytokine induction, iv. Chemokine induction, v. Granuloma formation, and 
vi. Expansion and subsequent contraction of activated CD4+ T cells.  
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As evident from the reviewed evidence, primary target cells for the adjuvant 
components are mononuclear phagocytes and dendritic cells, which can produce TNF-
α, IL-12, and IL-6. Early IFN-γ may come from NK cells, which may become involved as 
soon as IL-12 appears on the scene but may also be triggered more directly through a 
pathway involving their activating receptor, NKGD2, which recognize MHC-I-like 
antigens induced on several cells by stress signals [159]. Production of TFN-α can be 
presumed to play a role as inducer of other cytokines (such as IL-6) and chemokines. 
IL-6 may also play a role as stimulator and activator of T lymphocytes. A summary of 
the proposed actions of Freund´s on chemokine induction are illustrated in figure 5. 
 
Figure 5. Cytokines observed to be induced in the early phases following exposure to CFA (or 
mycobacteria) are TNF-α, IL-12, IL-6, IFN-, and several chemokines. Mycobacterial 
components are known to target mononuclear phagocytes and dendritic cells (involving toll-
like receptors) and to induce production of monokines, in particular IL-12 and TNF-a. IL-12 
induces NK cells to produce IFN-, which potentiates production of IL-12, forming a positive 
feedback loop (curved arrows). More direct stimulation of NK cells might take place via their 
activating receptor NKGD2, which recognizes stress-induced membrane ligands. TNF-a can be 
presumed to play a role as inducer of other cytokines (such as IL-6) and of chemokines. IL-12 is 
the driving force for directing T-cell differentiation to assume a Th1 profile. (Adapted from 
[158]). 
 
INTRODUCTION 
29 
2.8 Antibody purification 
2.8.1 Structure of an Immunoglobulin molecule 
Antibody (or immunoglobulin) molecules are glycoproteins composed of one or 
more units, each containing four polypeptide chains: two identical heavy chains H and 
two identical light chains L (Figure 6). 
The amino terminal ends of the polypeptide chains show considerable variation in 
amino acid composition and are referred to as the variable V regions to distinguish 
them from the relatively constant C regions. Each L chain consists of one variable 
domain VL and one constant domain CL. The H chains consist of a variable domain, VH, 
and three constant domains CH1, CH2 and CH3. Each heavy chain has about twice the 
number of amino acids and MW (~50,000) as each light chain (~25,000), resulting in a 
total immunoglobulin MW of approximately 150,000. Heavy and light chains are held 
together by a combination of noncovalent interactions and covalent interchain 
disulfide bonds, forming a bilaterally symmetric structure. The V regions of H and L 
chains comprise the antigen-binding sites of the immunoglobulin (Ig) molecules. Each 
Ig monomer contains two antigen-binding sites and is said to be bivalent. The hinge 
region is the area of the H chains between the first and second C region domains and is 
held together by disulfide bonds. This flexible hinge region allows the distance 
between the two antigen-binding sites to vary (Figure 6). 
 
Figure 6. The three-dimensional structure of IgG can be depicted as a Y-shaped molecule. Each sphere 
represents an amino acid residue. The light chains are shades of blue and the two heavy chains are 
shades of gray. (Adapted from www.wiley.com/legacy/products/subject/life/elgert/CH04.pdf). 
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2.8.2 Affinity purification of IgG using protein A/G  
Crude purification of antibodies can be accomplished by methods such as 
ammonium sulfate precipitation, thiophilic adsorbtion or affinity chromatography. In 
affinity chromatography (affinity purification), a ligand is coupled to a solid support 
material such as agarose gel. Sample fluids are passed through the support material, 
allowing immunoglobulins to bind to the immobilized ligand. After non-bound sample 
components are washed from the support, washing buffer conditions are altered so 
that the immunoglobulins are dissociated (eluted) from the immobilized ligand and 
recovered from the support in a purified form. Protein A and protein G are bacterial 
cell wall components that bind primarily to the Fc region of immunoglobulins and are 
by far the most accepted choices for affinity purification of IgG [160]. 
 
 
Figure 7. Purification scheme using protein A/G Nab spin kit column. 
 
2.9 Immunoprecipitation and antigen purification 
Many protocols rely on immunoprecipitation as the choice method for isolating 
small amounts of antigen or target protein from complex samples such as cell lysates 
[161, 162], serum [163, 164] and tissue homogenates [165, 166]. IP can be used to 
evaluate the differential expression of a protein and to characterize the proteins 
molecular weight, postranslational modifications, and interacting ligands. The 
antibodies used may be polyclonal or monoclonal, and may recognize the protein of 
INTRODUCTION 
31 
 
interest, a particular postranslational modification [167, 168], or an epitope tag [169, 
170] if the protein is overexpressed. The standard method for immunoprecipitation 
(IP) requires the incubation of the antibody with the sample containing the target 
protein (antigen). Once the antigen-antibody complex is formed, it is bound to Protein 
A or Protein G beads (typically cross-linked agarose) via the Fc region of the IP 
antibody. The beads and the sample are centrifuged to pellet the captured immune 
complex, the supernatant discarded and the beads washed and centrifuged again to 
remove any unbound proteins. For high-throughput applications, immobilized Protein 
A or G magnetic beads can be used to facilitate separation of the isolated immune 
complex from the remainder of the sample. The resin pellet is then exposed to 
denaturing conditions or low-pH conditions to dissociate the complex. The released 
proteins are typically analyzed via one-dimensional [171, 172] or two-dimensional gel 
[173] electrophoresis followed by mass spectrometry [171, 173] or immunoblotting 
[174, 175]. Both the antibody and target protein are released in the final step of the 
traditional IP technique. This can present a problem for 1D or 2D analysis of the target 
protein when the molecular weight is similar to the heavy chain or light chain of the IP 
antibody [176]. 
 For this reason, alternative methods have been developed to prevent the 
antibody from contaminating the target protein, including crosslinking the IP antibody 
to Protein A or Protein G beads [177, 178] or directly coupling the antibody to an 
activated support to create an immunoaffinity resin [179, 180], (Figure 8 and 9). 
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Figure 8. Diagram of the antibody bioconjugation chemistry. (A) Description of the antibody cross-linked 
method. (B) Schemes of the antibody-coupled method (Adopted from [176]). (C) Diagram of AminoLink 
reaction chemistry (reductive amination), a method for covalent, direct immobilization of IP antibody. 
The Pierce direct IP kit uses this method. 
 
 
 
Figure 9. Antibody coupling efficiency using the direct antibody immobilization method. Purified 
antibody (200 μg) from various species was coupled to 200 μl of AminoLinkCoupling Gel (settled gel) at 
room temperature for 4 h. For the chicken antibody, 500 μg was used (Adapted from[181]). 
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Some of these IP strategies have also become an effective tool in studying 
protein: protein interactions [176, 182, 183]. Co-immunoprecipitation (Co-IP) uses the 
antigen–antibody complex to isolate unknown proteins bound to the antigen (“bait-
prey” complex). Co-IP is a valuable in vitro tool to verify receptor-ligand or enzyme-
substrate interactions, to identify multiprotein complex formation and to confirm 
yeast two-hybrid results [169, 170]. As in IP, identifying and characterizing these 
unknown interacting proteins can be hampered by the presence of contaminating 
antibody heavy and light chains (Figure 10). Therefore, the advantages of the antibody 
immobilization methods outlined here also readily apply to Co-IP experiments.  
 
 
Figure 10. Diagram of a basic immunoprecipitation procedure. Antigen-containing sample (usually a cell 
lysate), antibody and beaded agarose affinity beads (usually Protein A or G) are allowed to bind. Non-
bound sample components are washed away, and then antibody and antigen are eluted with a buffer 
that disrupts the binding interactions. If reducing SDS-PAGE sample buffer is used for elution, antibody 
and antigen products will be denatured and reduced to component polypeptide fragments. 
 
2.9.1 Factors Affecting Immunoprecipitation 
Although IP methods are logically and procedurally simple, the variables and 
factors affecting success of any specific experiment are as numerous and peculiar as 
the specific differences between different individual proteins and different primary 
antibodies. Immunoprecipitation involves purification of a protein or complex of 
proteins using specific binding conditions. Empirical testing is nearly always required 
before IP conditions can be optimized to successfully isolate adequate amounts and 
purity of specific protein. Nevertheless, consideration of the main factors involved can 
help to identify the components that are most likely to affect particular experiments. A 
list of such factors and associated variables is described in (Table 4), followed by a 
discussion of several pertinent issues [4]. 
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Table 4. Factors that affect assembly of the purification complex. (Adapted from Immunoprecipitation 
technical guide and protocols, Thermo scientific). 
 
Factor   Variable Characteristic 
Method Format                                                 Column vs. batch method; spin vs. gravity columns 
Type of support                                                 Physical characteristics, capacity, non-specific binding 
Immobilization of Antibody                             Amount, orientation, method of attachment 
Immoilization of Bait                                        Tag, affinity ligand 
Order of Addition                                              For beads, antibody/bait and antigen/prey 
Lysate Pre-clearing                                           Non-specific binding 
Binding Buffer                                                  Components, stringency 
Wash Buffer                                                       Components, stringency 
Elution Buffer                                                   Components, elution strength 
 
 
 
Immunoprecipitation as performed by the batch method simply involves mixing 
the components of the reaction in a reaction vessel (usually a microcentrifuge tube) 
for a period of time to allow them to interact. At each step, the beads are separated 
from the solutions (nonbound sample, wash buffer and finally elution buffer) by 
centrifuging the tube to pellet the beads and carefully pipetting to remove the 
supernatant. 
Column methods involve incubating IP components with beaded resin that is 
packed in a plastic or glass column. The sample is either allowed to pass the column by 
gravity or centrifugation or the column is capped and the sample incubated with the 
resin (with optional mixing) to allow the antibody and antigen more time to bind. In 
either case, the sample solutions are separated from the beads by gravity-flow or 
centrifugal collection from the column tip. 
Large scale IPs (>10 ml resin) are generally limited to gravity-flow because of 
the impracticality of centrifuging large columns, especially if they are not designed to 
fit in a collection tube. Conversely very small scale applications require centrifugation, 
as just a few microliters of solution will not flow through a filter by gravity alone. Most 
medium scale IPs can be performed by either gravity-flow or centrifugation so long as 
suitable columns and collection tubes are available, and the beaded support is 
compatible with the increased pressures associated with centrifugation. 
The use of spin columns has a distinct advantage over both gravity columns and 
batch methods because almost all of the residual solution can be spun through the 
filter allowing cleaner separation of the solid and aqueous phases. Gravity columns 
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require constant monitoring to make sure the resin does not run dry and form air 
bubbles. In addition the antigen is eluted in multiple fractions, each of which must be 
monitored for the presence of antigen. Fractions containing antigen are normally 
pooled, therefore the volume will end up being much greater than the original sample 
and the antigen may require concentration. A disadvantage of the batch method is the 
formation of the resin pellet, which contains a significant volume of solution that 
cannot be removed by pipetting; additional wash and elution steps are necessary to 
obtain good purity and yield. 
 
2.10 Protein oxidation as a tool to identify new antimalarial antigens for vaccine 
development  
Upon Plasmodium infection of the RCB, both host and parasitic cells suffer 
significant changes in the pattern of protein oxidation, likely derived from the oxidative 
stress imposed by the processes associated to the metabolism of haemoglobin. Some 
of these changes have been recently characterized and associated with protection 
against malaria in Glucose-6-phosphate-deficient [184] and blood group O populations 
[185]. The identification of antibodies targetting carbonylated epitopes in the 
erythrocyte or the parasite in infected mice may thus be valuable to enrich the variety 
of candidate antigens suitable for vaccine formulations. 
Reactive oxygen species (ROS) are constantly generated within cells at low 
concentrations under physiological conditions, playing a part in the cellular redox 
regulation. Cellular production of ROS occurs both from enzymatic and non-enzymatic 
sources. ROS can also occur as the outcome of acute cell stresses and may result in cell 
death via apoptosis or necrosis. Cellular oxidative damage developes when the balance 
between ROS-generating systems and ROS-scavenging ones tilts in favour of the 
former. The primary cellular target of oxidative stress can vary depending on the cell 
type, the absolute level and duration of oxidant production, the species of ROS 
generated, its site of generation (intra- vs. extra-cellular), and the proximity of the 
oxidant to a specific cellular substrate. Proteins are major targets for ROS and 
secondary by-products of oxidative stress when these are formed in vivo either in 
intra- or extracellular environments, as they are the major component of most 
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biological systems and can scavenge 50-75% of reactive radicals such as ●OH [186]. 
There is increasing evidence that accumulation of oxidized dysfunctional molecules in 
the cell over a lifetime contributes to the reduction of its half-life [187, 188]. 
Some ROS-induced protein modifications can result in unfolding or alteration of 
protein structure, and some are essentially harmless events. Irreversible modifications 
such as protein carbonylation, and protein-protein cross-linking are generally 
responsible for permanent loss of function of the damaged proteins which are 
subsequently degraded or may progressively accumulate in intra-cytoplasmic 
inclusions as observed in some neurodegenerative disease [189]. In fact, such 
permanent modifications are implicated in the etiology or progression of a number of 
disorders and disease [190]. 
 
2.10.1 Protein carbonylation and carbonyl group detection 
Ros-mediated protein carbonylation is an important marker of protein 
oxidation and its measurement is thought to be a good and the most widely used 
indicator for the extent of oxidative damage of proteins associated with various 
conditions of oxidative stress, aging and physiological disorders [191].   
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Figure 11. Origins of carbonylated proteins. Protein carbonyl derivatives can be produced by different 
oxidative pathways. ROS can react directly with the Lys, Arg, Pro, and Thr side chains mainly through 
metal-catalysed oxidation (pathway 1). Direct oxidation of proteins by ROS can also yield highly reactive 
carbonyl derivatives resulting from the cleavage of peptide (pathway 2). Carbonyl groups may be 
introduced into proteins by adduction of reactive aldehydes derived from the metal-catalysed oxidation 
of polyunsaturated fatty acids (pathway 3). These lipoxidation products include α,β-unsaturated 
aldehyes which can undergo Michael-addition reactions and react with the sulfhydryl group of Cys, the  
ε-amino group of Lys or the imidazole group of His residues, di-aldehydes and γ-ketoaldehyes which 
react with Lys residues. Finally, carbonyl groups can also be generated by secondary reaction of the 
primary amino group of Lys residues with reactive carbonyl derivatives (ketoamines, ketoaldehydes, 
deoxyosones), produced by the reaction of reducing sugars or their oxidized products with lysine 
residues of proteins (pathway 4) [192].   
 
2.10.2 Determination of protein carbonyl groups  
 The classical approach to the detection of protein carbonylgroups involves 
their reaction with 2,4-dinitrophenylhydrazine (DNPH) followed by the 
spectrophotometric quantification of the acid hydrazone at 370 nm [193-195]. While 
this method has provided much valuable data on the correlation of carbonyl formation 
with oxidative stress, it has the disadvantage of requiring relatively large (up to 
milligram) amounts of protein. Furthermore, the limited solubility of many DNP-
derivatized proteins, and difficulties in eliminating free DNPH from the derivatized 
proteins [196], makes this method prone to interference [197, 198]. Other methods for 
carbonyl analysis include HPLC techniques [194, 199] based on the spectrophotometric 
detection of DNP-carbonyl derivatives after separation of the proteins by gel-
permeation or reverse-phase chromatography. HPLC analysis is useful for investigating 
purified proteins but is less useful in crude mixtures where problems with resolution 
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make it especially difficult to analyze low- and medium-molecular-weight proteins 
[200]. Carbonyl groups can also be detected by labeling with tritiated borohydride 
[193]. This technique is highly sensitive and specific when applied to samples of 
purified proteins, but high backgrounds and poor specificity (as tritiated brohydride 
also react with Schiff´s bases) can complicate its application to unfractionated tissue 
supernatant. 
Immunochemical techniques have been also applied to the detection of 
carbonyl groups in proteins separated by polyacrylamide gel electrophoresis [201, 
202]. Applying this approach, it is important to have reliable methods to identify 
specific oxidized proteins. It has been previously described an analytical procedure 
that allows both the reversible staining of total proteins and the specific 
immunostaining of the oxidized proteins separated on polyacrylamide gels [203]. 
However, a shortcoming of the procedure is that it requires the protein mixture (e.g., 
cell or tissue extract) be pre-derivatized prior to electrophoretic separation. For 
example, the protein derivatization of carbonyl functional groups with 2,4-
dinitrophenylhydrazine (DNPH) is used for antibody recognition of oxidized proteins. 
Unfortunately, this pre-derivatization alters the electrophoretic (and electrofocusing) 
properties of proteins. Consequently, it is not possible to directly compare the patterns 
from oxidized fingerprints with those from non-oxidized protein fingerprints that have 
been compiled into large database. The ability to conduct all derivatization and 
staining after electrophoresis and transblotting would offer many additional 
advantages over pre-drivatization procedures (e.g. determining oxidation of samples 
that have been blotted for prior experiments). Hence in the 3rd chapter of this work, 
we have applied a post-electrophoretic identification of oxidized proteins that could 
permit comparison of oxidation proteins with those that could identified with resistant 
ICR mouse serum to malaria [184, 204, 205]. 
2.10.3 Analysis of proteins by mass spectrometry (MS) 
Among the analytical techniques, MS holds a special place because it measures 
an intrinsic property of a molecule, its mass, with very high sensitivity and therefore it 
is used in an amazingly wide range of applications.  
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Biomolecules being large and polar, however, they are not easily transferred 
into the gas phase and ionized. Electrospray (ES) and matrix-assisted laser desorption 
ionization (MALDI) are the ionization techniques that should be credited most for the 
success of mass spectrometry in the life sciences. Currently, the uses of MS in 
proteomics are in three major areas. MS is the preferred technique for 
characterization and quality control of recombinant proteins and other 
macromolecules, an important task in the field of biotechnology. It is also commonly 
used for protein identification, either in classical biochemical projects or in large-scale 
proteomic ones. Finally, because MS measures the molecular weight of a protein, it is 
the method of choice for the detection and characterization of posttranslational 
modifications and potentially can identify any covalent modification that alters the 
mass of a protein. 
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3 OBJECTIVES 
 
Data in animal models support the idea of developing a malaria vaccine that 
can improve on natural immunity by either inducing more robust and potent immune 
response against a selected panel of antigens recognized as immunodominant in the 
context of natural infection or inducing a broader immune response against a large 
number of parasite antigens. Further, naturally acquired immunity in human and 
animals can be used as models for the development of a vaccination strategies to  
prevent infection or  death and severe disease. However, antigens and epitopes 
involved in this type of protection are largely unknown since remain unclear which of 
them   correlates with protection after experimental immunization or natural exposure 
. The challenge for next generation malaria vaccine is to identify which of the many 
antigen-specific responses might be predominantly responsible for protection, and 
selection of these antigens is needed for vaccine development.  
 Various studies in our laboratory, have shown that ICR mice populations are 
partially resistant to infection with lethal doses of Plasmodium yoelii 17XL (PY17XL). 
Remarkably, surviving ICR mice become fully resistant to PY17XL, showing an 
enhanced antibody response after a second challenge. These surviving mice could 
therefore be a suitable source of immunoglobulins for the identification of antigenic 
plasmodial proteins. In the other hand, upon plasmodium infection of the RBC, both 
host and parasitic cells suffer significant changes in the pattern of protein oxidation 
likely derived from the large amounts of reactive oxygen species (ROS) generated by 
the active metabolism of the multiplying malaria parasite and metabolism of 
hemoglobin. Hence, the identification of targeting carbonylated epitopes in the 
erythrocyte or the parasite in infected mice may help to identify new candidate 
antigens suitable for improved vaccine formulation. 
To pursue the previous hypothesis the research work here described was 
designed according to the following 3 objectives: 
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1- To develop a procedure designed to isolate and identify plasmodial proteins 
displaying strong reactivity against antibodies from naturally hyper immunized mice 
resistant to blood-stage malaria. 
2- To examine functionally the multiple affinity purified blood-stage parasite antigens 
from objective 1 with respect to their potential to induce protective immunity against 
lethal blood-stage malaria infection. 
3- To identify several novel posttranslational carbonylated antigens during the blood-
stage life cycle of Plasmodium yoelii 17XL, by using DNPH derivatization of oxidized 
protein and comparatively to identify several plasmodial potential vaccine antigens 
using malaria-resistant mice sera. 
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GRAPHICAL ABSTRACT 
Running title; New Plasmodium yoelii blood-stage antigens identified 
 
In this study, methods were designed to isolate and characterize plasmodial proteins 
displaying strong reactivity against antibodies from naturally immunized mice. The 
approach is useful for the identification of novel antigenic targets for new vaccine 
therapies. Interestingly, the system could be easily adapted to the identification of 
protective antigens recognized by the immune system in human acquired immunity to 
malaria or other infectious disease. 
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ABSTRACT 
As the search for an effective human malaria vaccine continues, understanding 
immune responses to Plasmodium in rodent models is perhaps key to unlocking new 
vaccine strategies. The recruitment of parasite-specific antibodies is an important 
component of natural immunity against infection in blood-stage malaria. Here, we 
describe the use of sera from naturally surviving ICR mice after infection with lethal 
doses of Plasmodium yoelii yoelii 17XL to identify highly immunogenic blood-stage 
antigens. Immobilized protein A/G was used for the affinity-chromatography 
purification of the IgGs present in pooled sera from surviving mice. These protective 
IgGs, covalently immobilized on agarose columns, were then used to isolate reactive 
antigens from whole P. yoelii yoelii 17XL protein extracts obtained from the blood-
stage malaria infection. Through proteomics analysis of the recovered parasite 
antigens, we were able to identify two endoplasmic reticulum lumen proteins: protein 
disulfide isomerase and a member of the heat shock protein 70 family.  Also identified 
were the digestive protease plasmepsin and the 39 kDa-subunit of eukaryotic 
translation initiation factor 3, a ribosome associated protein. Of these four proteins, 
three have not been previously identified as antigenic during blood-stage malaria 
infection. This procedure of isolating and identifying parasite antigens using serum 
IgGs from malaria-protected individuals could be a novel strategy for the development 
of multi-antigen-based vaccine therapies. 
 
Keywords 
Malaria; Immunoglobulins; Mass spectrometry; Antigens; Protein disulfide isomerase; 
Translation initiation factor 3; Plasmepsin; Heat shock protein. 
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INTRODUCTION 
Detailed understanding of the immune response in individuals who develop 
naturally acquired immunity to malaria infection could help identify valuable antigen 
candidates for new vaccine formulations. It is well established that B cells play a crucial 
role in the naturally acquired immunity to malaria observed in individuals living in 
endemic areas. This kind of immunity, which takes years to develop, is largely 
dependent on the acquisition of specific, protective antibodies directed against a 
repertoire of target antigens [1, 2]. Over the past years, the use of naturally resistant, 
susceptible, and genetically deficient mice, together with different Plasmodium strains 
has enabled the dissection of some of the immunological mechanisms developed 
against Plasmodium spp. infection in rodent models [3-6]. From these and many other 
studies, it is clear that both cellular and humoral immune responses are required to 
control and clear blood parasitemia. Nevertheless, it is well known that infections vary 
in virulence depending on the species and strain of both the infectious Plasmodium 
agent and the host rodent. Thus, different strains of inbred mice elicit antimalarial 
antibodies of diverse antigenic specificities [7]. Moreover, after primary malaria 
infection, serum samples collected on different days show distinct patterns of 
immunoreactivity [8], indicating temporal immunological modulation during infection.  
In non-lethal infections (e.g., those caused by P. chabaudi chabaudi or P. yoelii 
17 XLNL), recovery from infection generally results in immunity to a second challenge  
by the same strain or species of the parasite but not by a heterologous parasite [4]. 
Interestingly, the highly virulent L (lethal) strain of Plasmodium yoelii yoelii 17X 
(PY17XL) appears to activate Th2 but not Th1 cells, while the low-virulence NL (non-
lethal) strain activates both subsets of CD4+ T cells [9].  During P. yoelii infection, Th1 
cells producing interleukin-2 (IL-2), interferon-gamma (IFϒ) and tumor necrosis factor-ß 
(TNF-ß) activate macrophages to kill pathogens whereas Th2 cells, producing IL-4, IL-5 
and IL-10, assist B cells in producing antibodies [10]. Previous results from our 
laboratory have shown that ICR mice populations are partially resistant to infection 
with lethal doses of PY17XL [11]. Remarkably, surviving ICR mice become fully resistant 
to PY17XL, showing an enhanced antibody response after a second challenge [11]. 
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These surviving mice could therefore be a suitable source of immunoglobulins for the 
identification of antigenic plasmodial proteins.  
Immunoaffinity chromatography uses immobilized antibodies as affinity ligands 
specific to either an antigen or a group of structurally-related antigens [12]. In this 
study, we developed a procedure designed to isolate and characterize plasmodial 
proteins displaying strong reactivity against antibodies from naturally immunized mice. 
This approach is useful for the identification of novel antigenic targets for new vaccine 
therapies. Moreover, the system could be easily adapted to the identification of 
protective antigens recognized by the immune system in human acquired immunity to 
malaria or other infectious diseases. 
RESEARCH WORK 
52 
 
MATERIALS AND METHODS 
Malaria parasites and animals.  
The rodent malaria parasite Plasmodium yoelii yoelii 17XL (PY17XL) was kindly 
provided by Dr. Virgilio Do Rosario (Instituto de Higiene e Medicina Tropical, 
Universidade Nova de Lisboa) and stored after serial blood passages in mice. Infected 
blood was kept in liquid nitrogen in a solution containing glycerol 28% (v/v), sorbitol 
3% (w/v) and NaCl 0.65% (w/v). Random-bred ICR female mice (Hsd:ICR[CD-1]), aged 
6-8 weeks, were purchased from Harlan Laboratories. The mice were housed under 
standard conditions of light and temperature in the animal house of the Universidad 
Complutense de Madrid (Madrid, Spain). In vivo experiments were approved by the 
Animal Experimentation Committee of this institution. 
For parasite isolation and immune serum sampling, mice were inoculated by 
intraperitoneal injection of 107 red blood cells from P. yoelii -infected mice in 0.1 mL 
phosphate buffered saline (PBS). After infection, p-aminobenzoic acid at a final 
concentration of 0.05% (w/v) was added to the drinking water [13]. Parasitemia was 
monitored daily by microscopy examination of Wright's-stained thin blood smears. To 
assess protective immunity, the cured mouse fraction (about 20%) that spontaneously 
cleared the blood parasites was challenged with the same dose of parasites 40 days 
after their full recovery from the primary infection, and parasitemia was further 
monitored for 30 days as previously described [11]. Mice surviving this second 
challenge were considered malaria-resistant mice. 
 
Purification of mouse IgGs.  
IgGs from 150 µL-pooled serum samples of malaria-resistant mice were 
specifically bound onto a 0.2 ml NAbTM protein A/G column (Pierce) according to the 
manufacturer’s instructions. Briefly, binding buffer (sodium phosphate 100 mM 
containing NaCl 150 mM, pH 7.2) was used as diluent and as the binding and wash 
buffer. Bound IgGs were eluted in 400 µL fractions using the IgG elution buffer, pH 2.8 
provided. Collecting tubes were previously preloaded with 40 µL of Tris-HCl 1 M, pH 
8.5 for neutralization. Since amines (e.g., Tris) in the IgG fraction compete for coupling 
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sites on the resin for subsequent immobilization (see below), they should be removed 
by dialysis. Thus, each 1.2 mL fraction of purified mouse IgGs was dialyzed in a Slid-A-
Lyzer™ dialysis cassette (Thermo Scientific) against 500 mL of sodium phosphate 0.01 
M containing NaCl 0.15 M, pH 7.2 for 2 h, with a total of 3 replacements performed. 
After the third replacement, equilibrium was continued overnight at 4°C. Aliquots of 50 
µg (100 µL) of purified and dialyzed mouse IgGs were kept at -20°C until their use. 
 
Immobilization of mouse IgG.  
Immunoaffinity columns were prepared by immobilization of IgG antibodies 
from resistant ICR mice on agarose-loaded spin columns (Pierce Direct IP kit cat. n. 
26148)[14].  Briefly, 100 µL of AminoLink Plus coupling resin were applied to each 
column and centrifuged at 1,000 ×g for 1 min. The columns were then washed twice 
with 200 µL of 1x coupling buffer (sodium phosphate 0.01 M containing NaCl 0.15 M 
pH 7.2). Next, 50 µg of purified IgGs from malaria-resistant mice were loaded onto the 
column and the volume immediately adjusted to 200 µl using ultrapure water and 20x 
coupling buffer to give a final concentration of 1x coupling buffer. After addition of 3 
µL of sodium cyanoborohydride 5 M to allow covalent binding, the column was capped 
and incubated at room temperature with rotation for 2 h. Next, the column was 
washed twice with coupling buffer and pre-washed with 200 µl of quenching buffer 
(Tris-HCl 1M) to remove any uncoupled IgG. To block the remaining sites on the resin, 
the column was bottom capped again, 200 µL of quenching buffer plus 3 µL of sodium 
cyanoborohydride were once again added, and the column incubated for 15 min with 
gentle shaking. Finally, the column was washed twice with coupling buffer, 6 times 
with wash solution (NaCl 1M) and subjected to a final wash with TBS (Tris-buffered 
saline, Tris 0.025 M, NaCl 0.15 M; pH 7.2). 
 
Parasite extracts.  
P. yoelii-infected ICR mice were sacrificed under anesthesia when the 
parasitemia level averaged 50%. Blood containing a mixture of ring-, trophozoite- and 
schizont-stage parasites was collected in 0.1 M EDTA and kept at -80°C until use. For 
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total protein extraction, 5 mL of infected RBC were lysed with 0.1% saponin. The intact 
parasites were collected by centrifugation at 320 ×g for 5 min and washed with cold 
PBS by centrifugation at 7,800 ×g for 15 min until the supernatant was colorless. 
Parasite pellets were resuspended in extraction buffer (Tris-HCl 50 mM pH 8.0, NaCl 50 
mM, CHAPS 3%, Mega-10 0.5% and 1 tablet of complete Mini Protease Inhibitor 
Cocktail from Roche per 10 mL of buffer) and homogenized using a mini-potter for 10 
min at 4°C followed by 4 cycles of freezing (-20°C) and thawing (37°C). Homogenates 
were centrifuged at 20,000 ×g for 15 min and the supernatant recovered as the 
parasite whole protein extract and kept at -80°C until use.  
 
Isolation of parasite antigens by immunoaffinity.  
Total proteins extracted from PY17XL (500-1000 µg) in a 600 µL volume of TBS 
were loaded onto an antibody-coupled spin column and incubated for 2 h with gentle 
shaking. To remove non-bound proteins, the complex was washed three times with 
TBS and once with conditioning buffer (neutral pH, supplied with the Pierce Direct IP 
kit, Cat. No. 26148). Sodium deoxycholate 1% (w/v) (Sigma-Aldrich) in PBS was used to 
dissociate the bound antigens from the immobilized antibody and the eluate was 
recovered in PBS [15]. 
 
Protein determination.  
The Bio-Rad protein assay (Cat. No. 500-0006) and Bio-Rad DC protein assay 
(Cat. No. 500-0116) were used to determine protein concentrations in whole parasite 
extracts and in the solutions of purified antigens, respectively. 
 
Immunoblotting.  
Parasite total protein extracts, prepared as described above, were solubilized in 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing SDS 2.5 
%, boiled for 5 minutes and subsequently separated on 10% SDS-PAGE. After 
electrophoresis, proteins were transferred onto PVDF (Hybond-P, GE Healthcare) 
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membranes following standard procedures. Blots were blocked for 1 h with PBS 
containing 5% non-fat dried milk. The blots were subsequently incubated overnight 
with either serum or isolated IgGs from malaria-resistant ICR mice diluted in PBS 
containing Tween-20 0.05%. Bound IgGs were detected using HRP-conjugated anti-
mouse IgG (GE Healthcare) at 1/5000 dilution. Detection was performed using the 
SuperSignal chemiluminescence substrate (Pierce) and exposure to X-ray film. 
 
SDS gel electrophoresis of parasite antigens. 
 Parasite proteins isolated by immunoaffinity (20 µg) were diluted in 5x Tris-
glycine SDS sample buffer (Tris-HCl 50 mM, pH 6.8 containing SDS 2%, bromophenol 
blue 0.1%, β-mercaptoethanol 5% and glycerol 10%) to obtain a final concentration of 
1x Tris-glycine SDS sample buffer for optimal band resolution. Samples were loaded 
onto 10% gradient polyacrylamide Tris-glycine gels and size fractionated by SDS-PAGE 
(120 V, 90 min) followed by colloidal staining with Coomassie Brilliant Blue G-250 [16]. 
 
Tryptic digestion and MALDI-MS.  
Bands of the eluted antigens separated by SDS PAGE were manually excised 
from the SDS-PAGE gels, deposited in 96-well plates and automatically processed in a 
Proteineer DP (Bruker Daltonics, Bremen, Germany) for protein reduction, alkylation, 
and digestion with trypsin as described elsewhere [17].  After digestion, the 
supernatant was collected and 1 µL was spotted onto a MALDI target plate and 
allowed to air-dry at room temperature. Next, 0.4 µL of α-cyano-4-
hydroxytranscinnamic acid matrix (Sigma) 3 mg/ml in 50% acetonitrile were added to 
the dried peptide digest gel strips and allowed to air-dry at room temperature again. 
MALDI-TOF analyses were performed in an ABI 4700 MALDI TOF/TOF mass 
spectrometer (Applied Biosystems, Framingham, MA, USA) operated in positive 
reflector mode, with an accelerating voltage of 20 kV. Mass spectra were then 
collected for peptide mass fingerprinting (PMF). MS/MS data were submitting to the 
Mascot program version 2.2.04 (Matrix Science, London, UK) using GPS Explorer 
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version 4.9 to search in the nonredundant NCBI protein database (NCBInr 20090406; 
8,198,267 sequences; 2,824,199,726 residues). 
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RESULTS 
Integrity and variety of purified antibodies from malaria resistant mice.  
Protein A/G is a recombinant fusion protein that includes the IgG-binding 
domains of both protein A and protein G, allowing the binding of a broad range of IgG 
subclasses from a variety of mammalian sources. To evaluate the performance of the 
protein A/G system for the purification and isolation of IgGs from mouse serum, 
pooled sera obtained from malaria resistant ICR mice were loaded onto protein A/G 
columns and IgGs specifically eluted. The resultant eluate was analyzed by SDS-PAGE 
to determine the degree of purity and homogeneity of the recovered IgG fractions. As 
shown in Fig. 1A, most (>85%) of the recovered proteins from the acidic elution of the 
A/G columns were immunoglobulins, as revealed by the MW of the two major bands 
corresponding to the heavy (~50 kDa) and light (~25 kDa) chains of IgG.  
The integrity of the IgGs eluted from the protein A/G columns was verified by 
Western blotting of the purified IgG fraction and comparing this with that of the 
original loaded serum, further identified using anti-mouse IgG/HRP-linked F(ab). Fig. 1B 
reveals no difference between the purified IgG and intact serum, indicating no size 
changes incurred by both the heavy and light chains of the purified IgGs during the 
purification process with no signs observed of proteolytic degradation. 
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FIGURE 1. Affinity chromatography using serum protein A/G from malaria protected mice.  (A): SDS-
PAGE of serum proteins recovered after affinity purification on Nab A/G spin columns (lane P) compared 
to SDS-PAGE on intact serum (lane S). 10 µg were loaded per lane. M, molecular weight markers. (B): 
Western-blot analysis of purified IgGs (lane 1) and total serum (lane 2) from malaria-protected mice. 10 
µg of protein were separated through SDS-PAGE, transferred to PVDF membranes and detected using 
the secondary antibody anti-mouse IgG/HRP-linked F(ab). Arrows indicate the positions of the heavy and 
light IgG chains. 
 
We then checked the functionality and variety of the purified IgGs in terms of 
their specific binding to a large diversity of P. yoelii antigens by Western blotting of the 
parasite total protein. Thus, when we compared the signals produced by the purified 
IgGs and the crude serum IgGs (Fig 2A), the purified fraction was able to bind an 
identical protein pattern and range to the crude serum.  This confirms that the purified 
IgGs retain their antigen-binding functionality and variety.  
 
Purification and identification of parasite antigens potentially conferring malaria-
resistance.  
Having confirmed the wide range of antigen recognition and binding of the IgGs 
isolated from the malaria-resistance mice, we then covalently immobilized these 
purified IgGs in agarose resin. The resultant sample of IgG-agarose was evaluated for 
IgG integrity and functionality by Western-blotting as above, revealing similar behavior 
to the soluble IgGs (data not shown). 
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To isolate the parasite’s antigens, total protein extracts of P. yoelii were loaded 
onto the covalently-bound antibody column and eluted under stringent conditions to 
recover high-affinity bound antigens. The eluate was first tested for the presence of 
IgGs possibly released from the column, due to the stringent condition used, by 
Western-blotting with anti-mouse IgG/HRP-linked F(ab). Since no signal was obtained 
(data not shown), we concluded that the IgGs were not co-eluted in the flow-through. 
To examine the variety of antigens isolated, the same Western blot membranes were 
gently washed with PBS and re-incubated with immune sera from malaria resistant 
mice (as primary antibody) followed by incubation with anti-mouse IgG/HRP-linked Fab 
(as secondary antibody). As shown in Fig. 2B, a wide range of proteins reacting with 
the immune sera from mice were detected, indicating that the method was able to 
isolate antigens by high-affinity functional binding and recognition. 
 
 
FIGURE 2. Immunoreactivity against parasite proteins. (A): Western blot of whole P. yoelii 17XL protein 
extracts obtained from blood-stage infection in mice. Membranes were incubated with whole serum 
from infected mice (lane S) or with purified IgGs (lanes p, p1 and p2). Bands were detected using anti-
mouse IgG/HRP-linked F(ab). Exposure times were 10 min (s and p), 2 min (p2) and 1 min (p1). (B): 
Western blot analysis of the eluate (e) obtained by immunoaffinity of total parasite proteins through 
immunoaffinity with immobilized IgGs from malaria-resistant mice. The membrane was first incubated 
with pooled immune sera from mice and then with the secondary antibody anti-mouse IgG/HRP-linked 
Fab. All lanes were loaded with 10 µg of protein. SuperSignal (Pierce) was used as the chemiluminescent 
substrate for visualization. 
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To identify the major protein bands in the Western blots (Fig. 2B), these were 
excised from corresponding duplicate gels and subjected to MALDI-TOF to yield 
peptide mass fingerprints. It should be noted that the concentration of sodium 
deoxycholate used to dissociate the bound antigens from the immobilized IgGs is not 
compatible with the initial isoelectrofocusing partition of 2D gel electrophoresis, and 
thus 1D-denaturing gel electrophoresis of the eluate fraction was conducted for 
proteomic analysis. Moreover, due to the limited amount of eluate recovered from the 
immunoaffinity flow-through columns, 2D electrophoresis could not be performed 
after dialysis given the large amounts of isolated IgGs and parasite proteins that would 
eventually be required. From the sixteen 14 to 190 kDa bands excised and analyzed by 
MS (Figure 3), nine proteins were identified (Table 1).  
 
 
FIGURE 3. pY17XL protein bands selected for MS identification. Representative Coomassie blue stained 
SDS-PAGE of isolated antigens. Py: P17XL immunoaffinity purified proteins; M: molecular weight 
markers. Arrows indicate the bands excised for MS identification. 
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TABLE 1. Immunoaffinity purified antigens identified by MS/MS. 
Bands Accession n. Mass (Da) Score Protein 
1, 2 - - - Unidentified 
3 PLMN_MOUSE 
 
93460 
 
114 
 
Plasminogen OS=Mus musculus GN=Plg PE=1 
SV=2 
 
4 gi|82594363 
 
79303 98 
 
Heat shock protein [Plasmodium yoelii yoelii 
str. 17XNL] 
 
5 APOH_MOUSE 
 
39904 
 
179 
 
Beta-2-glycoprotein 1 OS=Mus musculus 
GN=Apoh PE=1 SV=1 
6 FIBB_MOUSE 
 
55402 216 
 
Fibrinogen beta chain OS=Mus musculus 
GN=Fgb PE=2 SV=1 
 
7 FIBG_MOUSE 50044 172 
 
Fibrinogen gamma chain OS=Mus musculus 
GN=Fgg PE=2 SV=1 
 
8 gi|82595601                                            56572 81 Protein disulfide isomerase [Plasmodium 
yoelii yoelii str. 17XNL] 
 
9 - - - Unidentified 
10 gi|82753379                                         52687 126 Plasmepsin [Plasmodium yoelii yoelii str. 
17XNL] 
 
11 gi|82594751 
 
37615 
 
67 
 
Eukaryotic translation initiation factor 3 - 39 
kDa subunit [Plasmodium yoelii yoelii str. 
17XNL] 
 
12 gi|82594751 37615 76 
 
Eukaryotic translation initiation factor 3 - 39 
kDa subunit [Plasmodium yoelii yoelii str. 
17XNL] 
 
13-16 - - - Unidentified 
 
Four of these were mouse proteins and five were of plasmodial origin. Band 
numbers 11 and 12 were the same P. yoelii protein and, thus, four different 
Plasmodium antigens were unequivocally identified: a member of the heat shock 
protein 70 family, protein disulfide isomerase, plasmepsin, and eukaryotic translation 
initiation factor 3. Table 2 summarizes the data obtained for these antigenic 
Plasmodium proteins.  The spectra of the identified proteins are included as 
Supplementary data. MOWSE score distributions were searched against proteins by 
the MASCOT software and matching peptide sequences mapped over the entire 
identified protein sequence. For all proteins, the MOWSE score distribution was 
significant greater than 73 (P<0.05).   
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TABLE 2.  Functional classification and protein description of identified Plasmodium proteins. 
Protein Description Database 
accession 
(Uniprot) 
Annotation 
Heat shock protein 70 
family 
 
 
Q7RER2 Molecular function: ATP binding, inferred from 
electronic annotation. Biological process: Response to 
stress. Also involved in chaperoning proteins into and 
through various compartments of the eukaryotic cell. 
Protein disulfide isomerase 
 
Q7RRT0 Molecular function: protein disulfide oxidoreductase 
activity. Biological process: cell redox homeostasis. 
Similarity: belongs to the thioredoxin family PFAM entry 
PF00085. Subcellular location: endoplasmic reticulum 
Plasmepsin 
 
Q7R9G3 Molecular function: aspartyl protease. Biological 
process: proteolysis. This family of aspartate proteases 
is classified by MEROPS as the peptidase family A1 
(pepsin A, clan AA). 
 
Eukaryotic translation 
initiation factor 3 39kDa 
subunit 
Q7RRX2 Molecular function: translation initiation factor, 
Biological process: protein synthesis. Comments: a 
WD40 repeat (also known as the WD or beta-
transducing repeat, PFAM entry PF00400) implicated in 
a variety of functions ranging from signal transduction 
and transcription regulation to cell cycle control, 
autophagy and apoptosis found in this protein. 
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DISCUSSION 
Most researchers agree that a global understanding of the malaria parasite’s 
biology and its associated molecular interactions with the host will help design 
effective antimalarial drugs and vaccines. The restricted immune response elicited by 
subunit vaccines featuring a small repertoire of epitopes has directed the attention of 
research efforts towards whole organism immunization [18-21] and multiple epitopes 
formulations [22, 23] to try to overcome limited immune recognition or 
polymorphisms in the target subunits. The search for candidate antigens based on 
molecular identification of essential parasite functions has also failed so far to provide 
effective immune protection [24].  
An alternative way to achieve protection against the parasite could be the use 
of parasite-targeted antibodies, found in individuals who have acquired protective 
immunity after malaria infection, to search out new target antigens [23, 25]. To 
explore this approach, methodological pathways for the isolation and characterization 
of these antigens need to be developed. As parasite-targeted antibodies, functional 
Plasmodium-specific IgGs isolated from immune sera could be effective. However, the 
quality, quantity and functional activity of IgGs recovered from animals experimentally 
immunized with recombinant parasite antigens or from humans endemically exposed 
to malaria are highly dependent on the purification method and the species [26]. In 
the present work, the high-affinity chromatography system used to purify IgGs proved 
to be adequate for the isolation of high quality functional IgGs from malaria-resistant 
mice, as indicated by their electrophoretic profile and their reactivity against P. yoelii 
proteins. 
IgG specificity can be exploited to search target antigens out of a complex 
sample mixture. Thus, the recovered IgGs were subsequently used for the purification 
and characterization of parasite antigens by immunoaffinity. The traditional method of 
immunoprecipitation by incubating an antibody with a protein sample and 
subsequently binding it to a protein A or G agarose matrix serves to efficiently recover 
target antigens [27-29]. However, immunoprecipitation followed by weak binding to 
agarose through protein A or G has certain intrinsic shortcomings such as the loss of 
insoluble antigen-antibody complexes [30], or the associated release of IgGs when 
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eluting the antigens [31]. In addition, if the antigens and IgG subunits are of similar 
molecular weight, it is difficult to separate out the immunoprecipitate [27]. The direct 
immunoaffinity antigen-enrichment method (Fig. 4) used here has several advantages: 
i) Co-elution of antigen and antibody is prevented, as the IgGs are first covalently 
bound to an immobilized matrix. This will also avoid the appearance of contaminating 
high- and low molecular weight antibody chains, which could hamper the identification 
of immunogenic peptides. ii) The immunomatrix can be reused several times, which is 
useful when working with limited immune serum. iii) The stringent conditions of 
elution means that antigens showing high affinity for the immobilized IgGs will be 
preferentially selected, increasing the chances of identifying valuable immunogenic 
peptides. iv) The recovered proteins are suitable for MS identification, offering the 
possibility of screening for new vaccine candidates.  
 
FIGURE 4. Summary of the antigen identification procedure. Sera from surviving ICR mice after Py17XL 
infection are used for IgG purification by protein A/G. IgG are subsequently immobilized by a procedure 
whereby reductive amination directly links the antibody to agarose beads. The coupling resin is provided 
in an activated state containing aldehyde groups formed by mild oxidation of adjacent diols using 
sodium meta-periodate. Primary and secondary amine groups on the antibody react with the aldehydes 
to form Schiff bases, which are then reduced by sodium cyanoborohydride to form secondary and 
tertiary amine linkages. The immobilized antibodies are thence used for purification and MS 
identification of antigenic peptides present in P17XL. 
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Using this procedure we were able to identify four highly-antigenic P. yoelii 
proteins. Remarkably, two of these proteins mainly occur in the endoplasmic reticulum 
(ER) lumen in the parasite: protein disulfide isomerase (PDI) and the HSPA5 member of 
the heat shock protein-70 family, which is also known as 78 kDa glucose-regulated 
protein (GRP-78) or binding immunoglobulin protein (BiP) in the corresponding 
mammalian homolog family. Coincidently, these two proteins are known to co-localize 
in the endoplasmic reticulum of rings, trophozoites, schizonts and merozoites during 
the intraerythrocytic growth of malaria parasites [12]. The ability of Plasmodium 
parasites to export proteins plays an important role in the parasite’s biology, including 
its virulence and probably the immune response produced in the host. In the middle of 
this export system occurs the specific trafficking of proteins from the ER to the 
parasitophorus vacuole and then to the host red cell cytoplasm (reviewed in [32]). 
Thus, the natural exposure of parasite PDI and BiP to the host immune system, as 
indicated by the reacting IgGs produced in our malaria-resistant mice, suggest a role 
for these two proteins in the ATP-powered machinery of the Plasmodium translocon of 
protein export [33]. This hypothetical role is supported by the existence of a 
multifunctional ATP binding domain in homologous BiP [34] and the partial co-
localization of PDI at the periphery of malaria parasites during red cell invasion [35]. 
Moreover, the affinity shown by the IgG antibodies raised in P. yoelii-resistant mice for 
PDI and BiP, identifies these two antigens as potential targets to elicit the necessary 
host immune responses to eliminate and control the blood-stage of the Plasmodium 
life cycle. It is also true that several Plasmodium antigens with a known role in the 
virulence and pathogenesis of malaria feature a large numbers of cysteine-residues at 
conserved positions within well-defined protein domains, and their correct disulfide 
linkage is essential for biological activity via PDI [36]. Examples of such protein 
domains include the F2-domain of EBA-175 [37, 38], the EGF-like domains of merozoite 
surface protein-1 [39], the ectodomain of apical merozoite antigen-1 [40] and host-
cell-receptor binding domains on P. falciparum erythrocytic membrane protein 1 [41].  
Although it is known that several other members of the HSP70 protein family of 
P. falciparum are immunogenic [42-46], it remains unclear whether the increased 
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levels of antibodies raised against these proteins are solely linked to parasite exposure 
[42, 46] or also to the acquisition of clinical protection [43, 45, 47].  
The immunoaffinity method used here also served to identify the unique P. 
yoelii plasmepsin, a key plasmodial aspartic proteinase.  In effect, this is the first time 
that plasmepsin has been identified as immunogenic in blood-stage malaria. The family 
of plasmepsins in P. falciparum is well defined and consists of ten members identified 
from the parasite’s genome sequence [48]. The plasmepsin family in P. yoelii is smaller 
than in other Plasmodium spp., as no orthologs of PfPM1, PfPM2 and PfHAP have been 
detected in the genomes of any of the six other species examined, suggesting that  
those species, including Plasmodium yoelii, contain a single food vacuole plasmepsin 
[49]. Plasmepsins participate in the first steps of hemoglobin degradation in the 
digestive vacuole of malaria parasites, which is a crucial process for parasite growth. 
Despite their functional redundancy in P. falciparum [50], plasmepsins have been well 
characterized as potential drug targets.  Indeed, functional and biochemical studies 
have been targeted at their inhibition aimed at halting hemoglobin digestion and 
eventually causing parasite death [51]. The idea that antibodies elicited against 
plasmepsin in our malaria resistant mice may have provided protective immunity 
against lethality is an attractive hypothesis. Interestingly, disruption of the single gene 
encoding plasmepsin-4 in the rodent malaria parasite Plasmodium berghei [52] 
generates virulence-attenuated parasites stimulating strong protective immunity 
against subsequent challenge with wild-type parasites. 
The eukaryotic translation initiation factor 3 (IF3) was also here identified for 
the first time as a presenting antigen during blood-stage malaria infection. IF3 is an 
essential factor for eukaryotic translation and has been suggested to play a role in the 
fine-tuning of amino acid availability responses and under conditions where aminoacyl 
tRNAs are in limited supply. Modified amino acid bioavailability during Plasmodium 
infection causes dysregulation of L-arginine metabolism [53] and modulates NO 
inflammatory responses [54]. Moreover, accurate control of IF3 expression limits the 
premature or inappropriate abandoning of translation that would otherwise 
compromise cell fitness (reviewed in [55]). Thus, blocking the functionality of this 
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essential factor by the host immune response remains to be explored to address the 
immunoprotective role of this newly identified antigen.  
The known antigen targets of protective host immune responses that could not 
be identified in our 1D electropherograms also deserve attention. Among these, 
merozoite surface protein 1 (MPS1) is a well-known antigen raised during protective 
immune responses and a potential vaccine candidate against both P. falciparum and 
other Plasmodium spp. [56, 57] MSP1 is synthesized as a precursor during schizogony 
and is thereafter processed on the merozoite surface into a membrane-bound, ≈19-
kDa fragment, which is carried into the newly invaded erythrocyte, and a soluble ≈33-
kDa fragment, which is shed from the parasite surface [58].  The protection of mice 
with the corresponding 19kDa fragment of P. yoelii MSP1 against malaria infection has 
been reported in this model [56]. Thus, although we could not identify MSP1 by MS in 
our immunoaffinity eluate, the presence of a classic MSP1 19KDa and related 
precursor band pattern was observed in the eluate’s 1D-electrophoregram (Figure 3: 
bands 13 to 16). This band pattern was also clearly observed in the Western blots 
prepared using resistant mice serum to identify the eluted antigens (Fig.2B). Moreover, 
the presence of IgG-reacting MSP1 in the total proteins extracted from P. yoelii was 
confirmed by 2D immunoproteomics using ICR resistance mice serum in 
complementary experiments in our laboratory (data not shown). 
The limited success of generating protective immunity against malaria using 
subunit vaccines composed of one or a few parasite proteins (or protein fragments or 
domains) has prompted the search for new antigenic proteins able to induce 
protective immunity. The circulating IgGs against blood stage malaria that maintain 
malaria as a subclinical disease in a proportion of the adult population exposed to the 
parasite constitute a major component of the immune response [1, 2]. This was the 
rationale behind our idea of the use of malaria-resistant mice after primary infection 
as a source of IgGs to search out P. yoelii antigens presenting during blood stage 
infection. Although there is still much to be learnt about protective immune responses 
in malaria, our results provide new direction for studies designed to identify new 
antigens in human malaria parasites as vaccine targets and reveal that a variety of 
proteins may offer efficient B cell-based protective immunity.  It is tempting to suggest 
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that a vaccine based on such a variety of antigenic proteins elicited during the parasite 
blood stage could be the key to effective protection against malaria [59, 60]. 
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Fig. S1. MS analysis of trypsin-digested peptides, distribution of MOWSE score by Mascot search and 
total and matched sequences (bold) of the identified PY17XL proteins: plasmepsin, heat shock protein, 
protein disulfide isomerase, 39kDa subunit of eukaryotic translation initiation factor 3; and mice 
proteins: plasminogen, beta-2-glycoprotein 1 and fibrinogen beta and gamma chains. Scores higher than 
73 were considered significant (P˂0.05). Matched sequences of the idenƟfied protein are shown in bold.  
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GRAPHICAL ABSTRACT 
 
IgGs from malaria resistant mice sera to lethal doses infection of Plasmodium 
yoelii yoelii 17XL, were purified and subsequently immobilized for isolation of blood-
stage parasite antigens. Immunoaffinity purified antigens were used to immunize 
BALC/c mice using CpG ODN1826 and Freund’s adjuvant system. Vaccinated mice serum 
at different days post vaccination was analyzed by western blot. Parasitemia and 
survival rate were also monitored after challenging infection. 
 
 
 
 
 CHAPTER 2 
 
87 
 
 
Abstract 
An effective malaria subunit vaccine remains elusive despite intensive efforts. 
Here a lethal malaria murine model was used to assess multiple affinity purified blood-
stage parasite antigens for the ability to induce immunity to blood stage malaria. For 
this study, we have generated malaria-resistant ICR mice to lethal doses of 
Plasmodium yoelii yoelii 17XL whose sera was used for purification of their infection-
induced IgGs. Immobilized IgGs were subsequently used to isolate blood-stage parasite 
antigens. These immunoaffinity purified antigens were used to immunize BALC/c mice. 
Western blot analysis of vaccinated mice serum at different days post vaccination 
showed an intensive immune response to large number of antigens with molecular 
weight ranging between 22 to 250 kDa. The level of protection obtained in vaccinated 
BALB/c mice after challenging to high lethal doses of P. yoelii yoelii 17XL was 
heterogeneous. Nonetheless, this immunization with multiple antigens isolated by 
immunoaffinity from intact native parasites induced a delayed infection of the 
erythrocyte resulting in a partial protection against malaria disease. This approach 
shows the potential to prevent malaria with a set of antigens isolated from blood-stage 
parasites.   
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GRAPHICAL ABSTRACT 
 
Taking advantage of post-electrophoretic DNPH derivatization of oxidized protein and 
using ICR mice sera resistant to lethal infection of Plasmodium yoelii 17XL, generated 
in our laboratory, several potential vaccine antigens were identically identified by both 
immunochemical and immunoproteomic methods during blood-stage life cycle of 
Plasmodium parasite. 
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Abstract 
The evidences from partial naturally acquired protective immunity to malaria 
infection in some individuals, in malaria endemic areas, have raised hopes to 
development of effective vaccines against malaria. Beside the elusiveness of 
immunological mechanisms involved in naturally acquired immunity, studies on 
malaria vaccine development suggest that the malaria immunity which lead to 
protection is highly dependent on the immune response against several parasite 
proteins which large number of them still remain unidentified. Hence, identification 
and analysis of immuno-protective parasite antigens would eventually results in the 
development of improved formulations for vaccine development. On the other hand, 
during blood-stage infection the parasite induce a high oxidative stress which 
oxidatively modify the proteins in the red cell environment, including host and parasite 
proteins. Herein, taking advantage of post-electrophoretic DNPH derivatization of 
oxidized protein, and using ICR mice sera resistant to lethal infection of Plasmodium 
yoelii 17XL generated in our laboratory, we have comparatively identified several 
potential antigens identically by both immunochemical and immunoproteomic 
methods, during the blood-stage life cycle of Plasmodium parasite. Beside 
identification of known potential target vaccine antigens like merozoite surface protein 
1 and merozoite surface antigen PY230, our results shown 6 fate protein newly 
identified:  heat shock protein 90, heat shock protein ClpB, co-chaperon GrpE, Cpn20 
protein, heat shock protein 70 and protein disulfide isomerase, these last two recently 
identified by immunoproteomic analysis. Notably, 2 out of 6 fate protein (co-chaperon 
GrpE and Cpn20 protein) were identified for the first time and likewise 5 novel blood-
stage plasmodial metabolic enzyme (adenosine deaminase, ATP synthase F1 subunit 
beta, dihydrolipoamide dehydrogenase and FAD-dependent glycerol-3-phosphate 
dehydrogenase and mitochondrial processing peptidase subunit alpha homolog) were 
additionally identified. Here, the hypothetical roles of the newly identified antigens as 
potential stimulator host immune response, and those already known vaccine target 
antigens, are discussed in details. Taking together, our finding with brief proposed 
hypothetical roles of those discovered novel antigens, may help to design further 
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5 General discussion 
 
In the present study, regarding the results obtained from protein A/G spin 
column and  IP kit (Chapter one), the Ig purification method was evaluated on the basis 
of purity, antibody specificity and functionality using resistance mice serum to malaria. 
When taking into consideration, both yield and purity, we concluded that the highest 
quality Ig could be achieved using protein A/G, also the optimal Ig purification methods 
relative to high-level Ag-specific Ig recovery and functionality for resistance mice 
serum. This is in agreement with methodology employed by other authors where 
rabbit and human Igs were also purified preferentially by protein A/G [236-238]. 
Immobilized bacterial surface proteins that interact with the Fc portion of IgG 
(Protein A—SpA, and Protein G—SpG) or with immunoglobulin light chains (Protein L—
PpL) are the most frequent affinity ligands for the purification of antibodies and 
genetically derived molecules (Figure 12) [160]. The binding properties of different 
bacterial proteins with respect to different antibodies from several mammalian species 
is given in Table 5.  
 
Table 5. Properties of the immunoglobulin-binding bacterial proteins A, G and L (+++ very strong 
binding; ++strong binding; + moderate binding; - no binding). 
 
Immunoglobulin Protein L Protein A Protein G 
Human Ig IgG +++ +++ +++ 
IgM, IgA, IgE, ++ + - 
IgD ++ + + 
Fab, F(ab`)2, scFv +++ + - 
Mouse Ig IgG1, IgG3 ++ + ++ 
IgG2a, IgG2b ++ ++ ++ 
IgM ++ + - 
IgA ++ ++ + 
Polyclonal Mouse ++ ++ ++ 
Rat ++ + ++ 
Rabbit + ++ +++ 
Goat, Bovine - + ++ 
Porcine ++ + + 
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Figure 12. (A) A PpL single domain binds simultaneously the VL region of two IgG Fab fragments, through 
a β-zipper interaction (PDB code: 1HEZ). (B) Fragment B of Protein A binds to the Fc domain of IgG (PDB 
code: 1FC2). (C) Protein G domain binding the Fc portion of IgG (PDB code: 1FCC). Taken from [230]. 
 
Moreover, according to the immunobloting follow up of the purification, no 
change in Ab affinity for Igs were observed. The ability to purify Ig from sera or plasma 
from immune animals or humans with a high yield and without selective loss of 
isotypes is imperative when conducting analytical experiments [236]. 
Apart from the in vitro analysis of humoral immune response, Igs are frequently 
batch-purified from serum for the purpose of passive transfer of the Ig as therapeutic 
agents into naive animals and even human host. In either case, it is imperative that the 
purification method dose not introduce artifacts, such as a bias in the Ig isotype, or 
alter the functional activity of the antibody molecules. 
From the results mentioned above and those that observed in chapter one, the 
procedure of purifying, isolating and identifying parasite antigens from serum IgGs of 
malaria-protected individuals are in especial interest for further study in the field of 
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immune response and vaccine developing approach and could be a novel strategy for 
the development of multi-antigen based vaccine therapies. Further, the identification 
of 4 plasmodial proteins in Plamodium yoelii blood-stage infection in chapter one, will 
help us to understand more in details in the biology of Plasmodium parasite. 
Although improved vaccine technologies have been central to attempts to develop 
more-effective pre-erythrocytic-stage vaccines (Figure 13) studies of asexual blood 
stages during the past 20 years have revealed a detailed array of molecules associated 
with parasite development and pathogenesis, and the natural acquisition of immunity 
[239]. 
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Figure 13. Vaccine Targets in Malaria 
 Liver-stage vaccines are designed to prevent malaria infection, but they must be 100 percent effective 
to protect people with no natural immunity (such as soldiers and travelers). They include vaccines 
containing whole killed sporozoites and those based on antigenic portions of sporozoite proteins. Most 
blood-stage vaccines seek to elicit antibodies to merozoites (the blood-cell–infecting stage of the 
parasite), since in people with natural immunity, such antibodies are associated with protection from 
clinical illness. Variability of blood-stage antigens among parasite strains has complicated vaccine 
development. Transmission-blocking vaccines would not protect the recipient but could help to prevent 
the spread of malaria. Sexual-stage parasite antigens are complex and have been difficult to produce. 
Multistage vaccines target antigens from multiple stages of the parasite’s life cycle. Some malaria 
researchers believe such a cocktail may be necessary for high efficacy, but these vaccines are 
complicated and expensive to make.  
 
At the molecular level, the advanced have been remarkable during this time 
and are set to continue with the genomic and proteomic data that are accumulating 
[240, 241]. That said, the asexual-blood-stage target antigen that is undergoing the 
most intensive investigation is still, as in 1985, the merozoite surface protein MSP-1. It 
was already recognized in 1985 that the asexual blood stage are the major target of 
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naturally acquired immune responses, that immunization with merozoite antigens 
involved red blood cell invasion is likely to be complicated by antigenic diversity and 
that the preferred molecules or epitopes for inclusion in a vaccine might, 
consequently, be those that are nonvariant [242].  Naturally acquired immunity in a 
highly endemic setting is a state of premonition. Individuals remain immune and 
asymptomatic because they have low-grade chronic infections [242]. This acquired 
immunity is induced predominantly by antigens that are polymorphic or that undergo 
clonal antigenic variation [14]. This contributes to the chronic state of infection by 
enabling the parasite to evade immune response. In one of the few clinical trials 
carried out with asexual-blood-stage antigens, vaccination with MSP-1, MSP-2 and the 
ring-infected erythrocyte surface antigen (RESA) reduced parasite density significantly, 
but this was a strain-specific effect [140]. 
Apical membrane antigen (AMA)-1, another vaccine candidate that has been 
known since 1985, is also highly polymorphic and, similary, induces strain-specific 
immunity [99]. Despite the (AMA)-1 is one of the top vaccine candidates because it can 
effectively inhibit the invasion of merozoites into red blood cells, this antigen has a low 
priority in vaccines considered for advanced clinical development because its antigenic 
diversity compromise vaccine efficacy [243]. However, it has been shown that 
chimaeras of two different antigens induce inhibition of two malaria strains [244]. In 
this case a comprehensive approach to map the immunodominant epitopes in 
different variants may help the design of novel molecules able to elicit a broad 
immune response. Additional efforts to broaden the response to AMA1 have been 
recently reported [245, 246]. The ability to engineer successfully antigens able to 
induce broad immune responses using structure based design of immunodominant 
epitopes has been shown in a recent work where the meningococcus antigen factor H 
binding protein, which is present in three different variants, was engineered to induce 
protective antibodies against all natural variants of the antigen [247].  
A fair conclusion that is drawn frequently from studies of natural immunity is 
that, for vaccine development, it would be better to focus on cryptic epitopes [240] 
rather than epitopes of the highly immunogenic polymorphic or clonally variant 
domains [248]. However, some promising liver- and blood-stage candidate vaccine 
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molecules have been selected after analysis of naturally acquired immune response 
[249, 250].  Also, the variant surface antigens (VSAs) of parasites that cause severe 
disease are different from and more immunogenic than those isolated from cases of 
mild malaria [251]. The possibility of exploiting this as a vaccine strategy should be also 
taken into consideration. Some of the candidate antigens under investigation are 
poorly immunogenic because they have a limited number of T-cell determinants; 
hence, they are MHC restricted and induce an immune response in only subsets of the 
population. There are ways to overcome this that have been known for a long time, 
notably coupling the relatively small vaccine molecules to carriers containing T-cell 
epitops [252]. Other features of the asexual blood stage of infection that could 
compromise the induction of a strong response to vaccines are that parasitized 
erythrocytes can suppress maturation of dendritic cells, thus impairing antigen 
presentation to T cells [238], and can cause apoptosis of malaria-specific T cells and B 
cells [242]. The emphasis on developing candidate asexual-blood-stage vaccines 
continues to be based on subunit strategies but, stimulated by studies from more than 
20 years ago, malaria-naive volunteers were recently shown to be fully protected 
against homologous challenge if immunized using extremely low-dose infecƟons by 
inoculaƟon of  3̴0 erythrocytes infected with P.falciparum on three occasions, with 
each infection being drug cured eight days after infection. Of particular interest is the 
observation that protection seemed to be cell mediated rather than antibody 
mediated [253]. This has the appearance of an innate, cytokine-mediated protection 
induced early in the infection [12]. However, this re-awakening of the whole organism 
approach to vaccination against blood stages requires further investigation to see 
whether there is a feasible way of exploiting it, perhaps by focusing on antigens that 
are targets of cell-mediated immunity [254]. However, the findings from the early 
studies using whole parasite approaches can now be viewed with a better 
understanding of the mechanisms of immunity, the characteristics of naturally 
acquired immunity to malaria [13], and explored in detail because of the major 
advances in both laboratory research capacity and biotechnology. Indeed, revising the 
early studies of protective immunity induced by radiation attenuated sporozoites [117] 
has led to one the most innovative advances in malaria vaccine research, namely the 
program by Hoffman and colleagues to develop a pre-erythrocytic vaccine using 
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radiation attenuated sporozoites. A brief summary of previous studies in rodents of 
whole killed and attenuated blood stage vaccines are presented in the following tables. 
 
Table 6. Mouse studies of blood stage immunization by infection-cure. 
 
Host species Vaccine Challenge Protection Notes Ref 
Mouse 
(CFI white) 
P.chabaudi 
 iRBC 106 
107 P. Vinckei 
106 P.berghei 
84% protection 
0% protection 
 [255] 
Mouse (CH3) P. vinkei; drug cure 
with chloroquine 
P. Vinckei 
P.berghei 
100% 
0% 
Killed parasites 
not protective; 
splenectomy 
attenuated 
immunity 
[256] 
Mouse (Swiss) P. chabaudi; drug 
cure with 
chloroquine 
P.berghei Delayed mortality  [257] 
Mouse  P. Vinckei; 
P. Chabaudi; 
P.berghei; P.yoelii 
Cross 
protection 
study 
All resistant to 
homologous challenge; 
cross-challenge protection 
varied with species 
 [258] 
Mouse (B-cell 
deficient) 
 
P. Vinckei; P. 
Chabaudi; 
P.b.yoelii; drug cure 
with chloroquine as 
required 
Cross 
protection 
study 
Varied with species; 
improved survival in most 
cross-protection studies. 
 [259] 
Mouse CBA/Ca P.berghei; P. 
Chabaudi AS, 
P.chabaudi DS 
Cross 
protection 
study 
All resistant to 
homologous challenge; 
cross-challenge protection 
varied with species 
 [260] 
Mouse CBA/Ca P. Chabaudi AS, P. 
Yoelii 17XL 
Cross 
protection 
study 
P. chabaudi AS with 
natural cure protected 
against homologous and 
heterologous challenge. 
Effect of drug cure on 
subsequend 
development of immunity 
depended on the 
timing of drug 
administration 
Early drug cure 
prevented 
development of 
protection 
to homologous 
and 
heterologous 
parasites. 
[261] 
C57BL/6j mice 105 P. chabaudi x 3 
doses with drug 
cure 
106 iRBC 
(homologous 
& heterologous 
strains) 
Attenuation of 
parasitemia; heterologous 
protection 
 [262] 
Mouse (BALB/c) P. yoelii 105 iRBC 
with 
drug cure x 1 
P. yoelii 105 
iRBC 
100% protection Protection 
against 
sporozoite 
challenge. B 
cells 
required for 
protection 
against blood 
stage 
[263] 
Mouse (BALB/c) P. yoelii (256BY 
nonlethal) 
drug cure with 
chloroquine 
P. yoelii (256BY 
& 
17X non-lethal 
strain) 
100%  [264] 
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Table 7. Mouse studies of blood stage immunization with blood stage parasite fractions. 
 
Host species Vaccine Challenge Protection Ref 
Mouse (AJ) P. berghei lysate x 1 P. berghei 100% protection with crude 
lysate and high level 
protection with certain fractions. 
[265] 
Mouse P. chabaudi merozoites (104–
106) 
in FCA x 2 
P. chabaudi 
iRBC 
(106–108) 
50% survival in lethal (106) 
challenge following 106 
x 2 vaccinations 
[266] 
Mouse P. berghei, P. vinckei, P. 
chabaudi,  
P. yoelii 
Cross 
protection 
study 
All resistant to homologous 
challenge; crosschallenge 
protection varied with species 
[258] 
Mouse (AJ) P. chabaudi 107 iRBC + Alum 
+ IL-12 x 2 doses (2nd dose no 
IL-12) or 107 iRBC + Alum + 
CpG x 2 doses 
106 iRBC 100% protection from lethal 
challenge 
[267] 
 
 
Table 8. Rodent studies of blood stage immunization with irradiated/attenuated parasites. 
 
Host species Vaccine Challenge Protection Notes Ref 
Mouse (albino) Irradiated P. 
berghei; 
immunizations 
with irradiated 
iRBC (1 x 
108) x 5 doses 
 significantly delayed 
mortality, with 5/35 
(14% survival) 
 [268] 
Rat Irradiated P. 
berghei 
 significant attenuation 
in challenge 
parasitemia following 
single or multiple 
doses of irradiated 
iRBCs 
Non-lethal 
model; 
[268] 
Mouse (ICR) Irradiated P. 
berghei; 
immunizations 
with irradiated 
iRBC 
(1 x 108) x 5 doses 
 significantly delayed 
mortality, with 6/10 
surviving low dose 
challenge 
survival related 
to challenge 
dose 
[269] 
Mouse (ICR) Irradiated P. yoelii P. yoelii 
sporozoites 
Attenuated 
parasitemia 
 [269] 
Mice (BALB/c) P. berghei 107 
radiation- 
attenuated 
parasites 
P. berghei 106 7/11 Protected against 
lethal challenge 
 [270] 
Mice (BALB/c) P. yoelii 5 x 106 
radiation- 
attenuated 
lines 
P. yoelii 104 5/5 Protected against 
lethal challenge 
 [271] 
Mouse (BALB/c) Attenuated P. 
yoelii 
P. yoelii 
(YM lethal strain 
100%  [272] 
      
 
 
The growing realization of the likely limitations of recombinant protein-based 
malaria vaccines, coupled with a better understanding of the protective immunity to 
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malaria, both in animal models and in naturally exposed human populations and 
experimentally infected volunteers, as well as the increased capacity to manipulate 
parasites provides new impetus to evaluate whole blood stage parasite approaches to 
malaria vaccine development. Progress made in pre-erythrocytic radiation attenuated 
parasites as malaria vaccine candidates and recent advances in constructing stable 
genetically attenuated parasites provide further support to this. While it appears that 
so-called sterile immunity may be a difficult goal to achieve with a blood stage whole 
parasite vaccine, recent clinical experimental studies [253, 273] indicate that robust 
protective immunity may be a realistic goal and the anti-disease protection that such a 
vaccine would confer would complement the efficacy of any pre-erythrocytic vaccine 
which, if less than 100% efficacious would still make populations vulnerable to the 
potentially lethal outcome of breakthrough blood stage infection. It is likely that any 
blood stage parasite vaccine using whole killed parasite material will need to be 
formulated and delivered in a way to elicit a protective cellular immune response. In 
this respect, the selection of a potent and safe adjuvant will be a critical step [156]. 
Safety issues such as red cell alloimmunization and adventitious infectious agents will 
need to be addressed. An alternate approach is the use of live but genetically 
attenuated parasites. There is much optimism for this approach for pre-erythrocytic 
vaccines, and there is emerging data on the potential utility of parasites with stable 
genetic attenuation [272]. However, in addition to the biosafety issues referred to 
above, an ability to cryopreserve parasites or another technical solution for vaccine 
delivery will be required. 
Effective vaccines for malaria must reproduce or, even better, improve 
naturally acquired immunity. However, the latter, which is directed primarily against 
asexual blood stages, requires repeated exposure and involves persistence of 
infection, responses to complex antigenic polymorphisms, immune modulation and 
immune evasion. On the basis, it has been argued that, to be effective, a vaccine 
should not induce a sterilizing immunity, certainly against the clinically important 
phase of infection [274]. The goal for pre-erythrocytic (and transmission-blocking) 
vaccines remains the prevention of all parasite development, but this is far from being 
achieved at presents. It is doubtful whether any of the vaccines currently scheduled for 
clinical trials will, on their own, have the efficacy and long-term effectiveness to justify 
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widescale use. This will probably be achieved only with combination, multi-component 
vaccines. 
A vaccine that is good enough to be an effective alternative to treatment and 
vector control remains a more distant goal and might require another 20 years to 
perfect [239]. 
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5.1 CONCLUSIONS 
 
The experimental results presented in this thesis provide new insights into 
malaria multi-antigen-based vaccine therapies and the redox biology of the malaria 
parasite. According to our results we can raise the following conclusions: 
1- A protein A/G system allowed the purification of different subclasses of IgGs 
from malaria-immunized mice. The results obtained with the A/G system 
demonstrated that the high-affinity purified IgGs retain their structure and 
functionality throughout the purification processes. 
2- The combined approach of protein A/G immunoglobulin purification, antigen 
enrichment by immunoaffinity using immobilized immunoglobulins and the 
identification of the obtained proteins by mass spectrometry was used for the 
search of novel potential antigens in blood-stage Plasmodium yoelii lethal 
malaria infection allowing the identification of four peptides: protein disulfide 
isomerase, a member of the heat shock protein 70 family, plasmepsin and a 39 
kDa-subunit of the eukaryotic translation initiation factor 3. One or more of 
these proteins may be suitable for further testing as components of vaccine 
formulations. 
3- Freund´s adjuvant system and subcutaneous route of inoculation were 
appropriate approaches to stimulate mice immune system, allowing the 
isolation of multiple antigens by immunoaffinity. 
4- The combined set of antigens obtained after purification by immunoafinity of P. 
yoelii proteins triggered a good immune response in vaccinated mice, however, 
infection of mice with lethal doses of P.yoelii 17XL resulted only in partial 
protection against malaria disease, showing lower parasitemia profiles and 
delayed death as compared to untreated controls.  
5- Six P. yoelii 17XL carbonylated proteins recovered from infected mice 
erythrocytes were identified by immunoblots and MS analysis as novel 
immunogenic candidates: co-chaperon GrpE, Cpn20 protein, FAD-dependent 
glycerol-3-phosphate dehydrogenase, dihydrolipoamide dehydrogenase, ATP 
synthase F1 subunit beta and adenosine deaminase. These proteins may be 
involved in essential maturation and metabolic processes during the 
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erythrocytic cycle of Plasmodium, and either alone or in combination with the 
previously identified immunogenic proteins  may be used in model systems to 
test candidate vaccines.  
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